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Abstract 
COG is a protein complex (units 1 -8) involved in retrograde transport of the resident Golgi 
proteins in intra-Golgi retrograde transport. Mutation in cog7 gene leads to congenital 
disorder of glycosylation (CDG-COG7) which causes severe mental retardation and, in some 
cases,death. There is significant amount of literature that describes glycosylation disorder in 
COG7 patients, but there is no data describing PGs from CDG-COG7. 
Metabollic labelling with WB and MS was performed. 
COG7 cells secrete high Mw PG with extensive sulfation level. The main  modification of the 
PG in secreted fraction is CS -95% ,and HS comprises of  5 %. Cellular proteolgycans show 
reduced synthesis of HS 65% compared with healthy 85%. 
Secreted proteolgycans from COG7 showed reduced PG variation and the presence of 
serglycin was detected. Intracellular decorin was detected in COG7 cells with possible 
formation of  complexes with collagen type I or type II. Aggrecan PG was detected 
intracellularly as well as in a secreted form. 
Distorted recycling mechanism of uptaken proteins was discovered with long delay in release 
of uptaken protein. 
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Aim 
Congenital disorders of glycosylation (CDGs) are a group of genetic syndromes affecting 
many patients. Most of the syndromes have severe consequences leading to multiple adverse 
conditions (e.g. mental retardation, failure to thrive) and, in some cases, death. CDGs affect 
glycosylation pathways in the cell and have global effects. Recently, the incidence of CDGs 
is low due to high misdiagnosis. It is proposed that there are approximately 1 million people 
diagnosed with CDGs in the world, although the real incidence number is, presumably, much 
higher. 
Conserved oligomeric Golgi (COG) complex is an important eight-subunit protein complex 
that functions in Golgi organelle and it is implicated in retrograde transport within Golgi and 
between Golgi and ER. COG7 is one of the COG’s subunits and patients with mutated cog7 
gene have shown affected glycosylation pattern. Mutation in cog7 gene leads to reduced level 
of COG7 protein and the N-glycosylation and O-glycosylation pattern is, in turn, affected, 
according to current literature. However, there is no data that describes PG O-GAG 
glycosylation in COG7 patients. It is possible that this glycosylation pathway is affected in 
the same manner as N-glycosylation and O-glycosylation. On the other hand, it is entirely 
possible that O-glycosylation is not affected in COG7 patients. 
Proteoglycans (PGs) are glycans where the biological and chemical characteristics are 
determined by the attached sugar nature, rather than protein. The most abundant modification 
carried out on PG is glycosaminoglycan chain(s) (GAG(s)) attachment on serine residue. 
GAGs are long polysaccharide chain (essentially a polymer), up to a hundred residues, that 
are essential for determination of PG characteristics. Different GAG types (chondroitin, 
heparan, keratan) are present on PGs and are instrumental in the glycan’s function (ligand 
binding, water binding). PGs are synthesized in ER and modified in Golgi, where 
biosynthesis of GAG chains occurs. 
If COG7 patients have aberrant N-glycosylation, is it possible that the PG synthesis is also 
aberrant? How does it relate to COG complex function?  There is no data that answers this 
question. 
In this project, we tried to establish the nature of secreted and cellular PGs from fibroblasts of 
COG7 patient. Are they different than healthy fibroblast’s PGs? If it is so, to what extent are 
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they different? Moreover, how does the change of PGs synthesis relates to COG complex 
functionality, especially in the light of the retrograde transport function? 
Overall aim of this project was to establish ground work for future project involving COG-
mutants and PG synthesis. In this way, one can learn more about GAG synthesis and protein 
transport within the Golgi apparatus. 
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1 Introduction 
1.1 The Golgi apparatus 
1.1.1 The Golgi apparatus origins and structure 
The Golgi apparatus is a crucial organelle in the cell responsible for sorting and processing of 
various cargo proteins, both soluble and transmembrane. Its origin goes as far as to the 
common eukaryotic ancestor. Its structure varies between species. In most organisms the  
Golgi apparatus is organized in a stack-like fashion with flattened membrane structures 
(known as cisternae) acting as basic building blocks to form a polarized (cis, medial and 
trans- orientation) moiety. The cis side of the Golgi organelle system faces the nuclear side, 
while medial cisternae are stacked between cis and trans-cisternae that face towards cell 
periphery.  
 
Figure 1. Schematic representation of the Golgi apparatus; adopted form THE CELL(Bruce 
Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts 2002). 
Although the Golgi apparatus shares similarities in general structure, the actual appearance of 
it can change. In mammals, it forms a ribbon like membrane structure via lateral connection, 
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while in plants and invertebrates the Golgi apparatus exist as separate bodies disposed 
throughout the cytosol. Moreover, in yeast, different Golgi cisternae are present as separate 
compartments within the cell(Wilson et al. 2011).  However, there is a group of organisms 
that lack visible Golgi stacks into which we can include parasites (e.g. Giardia intestinalis) 
microsporidia, heterolobosea and numerous apicomplexans (Babesia, Theileria)(Mowbrey & 
Dacks 2009). Although it is well known that the Golgi apparatus functions as a sorting centre 
for transmembrane and soluble proteins, it is also regarded as a glycan factory and it also 
possesses a number of different functions which include proteolytic processing (Stamnes 
2004) and lipid homeostasis(Wilson et al. 2011). 
 
1.1.2 Protein transport to Golgi apparatus 
 
Newly synthesized cargo proteins arriving to the Golgi apparatus are coming from ER exit 
sites via vesicular bodies covered with COP II (coatemer protein II) proteins. This system 
regulates secretory cargo concentration in anterograde transport (from ER to Golgi). Cargo 
that needs to be returned back to the ER is transported in COP I type vesicles via vesicular 
transport mechanism that regulates recycling of cargo back into ER.(Lee et al. 2004) The 
fusion between COP II vesicles and the Golgi apparatus occurs, in mammalian cells, at the 
ERGIC (ER-Golgi intermediate compartment) site. There is evidence suggesting that ERGIC 
is the primal sorting site for the cargo that is destined to be recycled to the ER from cargo 
targeted for the cis -Golgi. This primal sorting is achieved by recognition of amino-acid 
motifs in the recycled proteins that determine their subsequent faith. Even though there is 
evidence showing presence of the ERGIC,  in several cell types the stability and dynamics of 
this “organelle” are still elusive(Wilson et al. 2011). 
1.1.3 Protein transport through the Golgi apparatus 
When cargo molecules reach the cis-Golgi, they must pass through the cisternae within the 
stacks to be completely modified and sorted to their appropriate destination. In today’s 
scientific community, several different models have been proposed to explain how cargo can 
traverse the Golgi’s cisternae. Three independent models are: 
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1. The cisternal maturation model (CMM) 
2. The vesicular transport model (VTM) 
3. The rapid partitioning model (RPM)  
1.1.4 The cisternal maturation model 
This model projects that cisternae are formed on the cis-side of the Golgi apparatus and then 
progress through the Golgi stack while carrying secretory cargo molecules in order to form 
exit vesicles at the trans-side of the Golgi. It is believed that Golgi-resident proteins recycle 
between “old” and “new” cisternae via retrograde vesicular transport using COP I-type 
vesicles that  interact with the COG (conserved oligomeric Golgi) complex (Suvorova et al. 
2002). There is much supporting evidence towards the cisternal maturation model and it is a 
prevailing model accepted by the majority of researchers(Emr et al. 2009). Obtained 
morphological data fit well with the CMM, due to the fact that cisternae constituted at the cis-
side and disintegrate (or “peel off”) at the trans-side. This model also explains how large 
cargo molecules (i.e. bigger than transport vesicle) could be secreted (e.g. procollagen in 
mammalian fibroblasts) and the model also incorporates COP I vesicles and the fusion 
machinery components in its mechanism. In this model, COP I vesicles act as retrograde 
carriers of resident Golgi proteins and therefore one can explain why given Golgi resident 
proteins are present in a number of different Golgi compartments as well as why Golgi 
resident proteins move rapidly within and between different Golgi cisternae (Emr et al. 
2009). Similarly,  the CMM could project clear predictions with respect to: cargo speed 
through Golgi cisternae, composition of resident proteins in maturing Golgi cisternae that 
should vary over time and that cisternal maturation should require COP I vesicles. There is 
clear evidence that procollagen and the VSV-G transmembrane glycoprotein move through 
Golgi stack at the same rate. The cisternal composition of resident proteins is dynamic and 
was visualized by live-cell fluorescence microscopy, and the rate of the cisternal maturation 
was similar to the transit speed of secretory cargo, suggesting that cisternal maturation fits, 
with observation of anterograde transport in the Golgi apparatus. Moreover, COP I deficient 
yeast cells had slower maturation of cisternae compared with the wild type (Emr et al. 2009). 
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1.1.5 The vesicular transport model 
In this model, also known as the stable compartment model, each Golgi stack is a stable 
structure and cargo molecules are transported into cisternae via specialized transport vesicles. 
It was first suggested by Rothman and Wieland in 1996 (Rothman & Wieland 1996). In this 
model resident Golgi proteins are retained in cisternae while secretory cargo molecules are 
moved, from one cisterna to the next, by anterograde COP I- coated vesicles (Emr et al. 
2009).This model has a number of advantages: it explains the polarity of the Golgi stack and 
gives reason for the abundance of COP I vesicles in proximity to the Golgi. The polarity of 
Golgi is achieved due to the notion that each cisterna has a distinctive set of resident proteins 
therefore it could be viewed as a distinctive organelle. Abundance of COP I vesicles around 
the Golgi membranes could be explained by their formation and fusion at the cisternal rims. 
However, this model has encountered a number of conflicting evidence (Bonfanti et al. 1998) 
which raises doubts about its validity. The most prevalent evidence is that the Golgi can 
transport and secrete cargo molecules that are larger than what a secretory vesicle can 
accommodate (e.g. procollagen in mammalian fibroblasts and scales in algae). This could be 
explained by the existence of mega-vesicles, but no putative mega-vesicles are seen in algae 
and procollagen seems to remain in the Golgi cisterna. (Bonfanti et al. 1998) 
1.1.6 The rapid partitioning system 
In this model, proposed by Patterson et al. in 2008 (Patterson et al. 2008), cargo is predicted 
to exit the Golgi apparatus with exponential kinetics rather than showing a distinctive lag 
phase which would be observed if the cargo would follow the cisternal maturation model. 
Secondly, this model shows that upon entry, transmembrane cargo quickly distributes itself 
throughout Golgi membranes and subsequently divides itself into two diverse membrane 
environments. Patterson et al proposed that there are two distinctive membrane regions: a 
processing domain and a secretory domain. In the processing domain one can find a large 
number of cargo-processing enzymes, while secretory domains are capable of forming 
transport intermediates. The different domains in the Golgi membranes possibly arise due to 
different composition of membrane lipids. In this model, the secretory domain is modelled to 
be enriched in cholesterol and glycosphingolipids, whereas the processing domain is mainly 
composed of glycerol phospholipids (Patterson et al. 2008). 
 
 INTRODUCTION 
 
5 
 
1.1.7 The Golgi apparatus - a glycan factory 
The Golgi apparatus can be named a glycan factory, as almost all pathways for glycosylated 
proteins and lipids pass through this organelle. 
After initial processing, glycoconjugates leave the ER and travel towards the Golgi stacks. 
Almost all glycoproteins are exposed to trimming and extension as they pass through a Golgi 
stack. In the case of N-glycosylation (most common glycosylation mechanism for proteins), 
the glycoprotein already possesses an oligosaccharide which is then trimmed and/or extended 
by actions of enzymes that are present in the Golgi lumen (Reynders et al. 2011).  
PGs acquire their GAG chains in the Golgi apparatus ,thus Golgi acts as a glycan synthesis 
centre for PGs as well as for other O-linked glycoproteins (Prydz & Dalen 2000). 
The Golgi apparatus is not only a harbour of glycosyltransferase enzymes but provides 
substrates for glycan biosynthesis. UDP-sugar, GDP-sugar and PAPS (3`-phospho-adenosine-
5`-phospho-sulfate) specific transporters translocate UDP-sugars, GDP-sugars and PAPS 
(substrates) from the cytoplasm into the Golgi lumen; this translocation process is energy-
dependent. Saccharides are supplied via dietary routes and converted into UDP-sugars in 
cytoplasm(Caffaro & Hirschberg 2006).  
 
1.1.8 Proteoglycans (PGs) synthesis 
PGs are protein structures with one or more GAG chains attached via O-glycosylation of 
serine residues with neighboring glycines in the peptide backbone. In contrast to 
glycoproteins, where the scientific focus is mostly on the protein part, it is the glycan nature 
that gives the PG its subsequent characteristics.  
1.1.9 Types of proteoglycans 
Small leucine rich PGs (SLRP) contain a protein core with leucine rich repeats with N-
terminal cysteine cluster, “ear repeats” and at least one GAG chain. Those PGs form a family 
with sub-classes- traditionally defined classes I-III and non-canonical classes IV and V. 
SLRP are important in a number of biological functions: binding to collagen, inhibition of 
cell growth or modulation of bone morphogenic protein (Schaefer & Schaefer 2010). Decorin 
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is a prototype member of SLRP, consisted of 359 amino acids with Mw of 39 kDa. There are 
five isoforms of decorin and canonical isoform possesses one O-glycosylation site (GAG) 
and three N-glycosylation sites. It is mostly secreted from cell and localized in the 
extracellular matrix (Uniprot n.d.).Decorin is able to bind transforming growth factor-β 
(Hildebrand et al. 1994). Biglycan is another member of SLRP family. It is a PG with 368 
amino acids constituting 41 kDa of Mw. Biglycan is mostly secreted from cells and is found 
in the extracellular matrix. It has four possible O-glycosylation sites (GAG) and two N-
glycosylation. There is only one isoform of biglycan and it is capable of binding, as well as 
decorin, to transcription growth factor β (Uniprot n.d.; Hildebrand et al. 1994) 
Serglycin is a PG expressed mostly in hematopoietic and endothelial cells. It plays a vital role 
in formation of mast cells secretory granules and is required for storage of some proteases in 
connective tissue. It has a 158 amino acids protein core and its Mw is 17 kDa. It possesses 
eight O-glycosylation sites (GAG) with two sites experimentally proven and six potential 
sites; no know isoforms are reported. The GAGs attached to serglycin are of CS and HS 
nature (Uniprot n.d.; Kolset & Tveit 2008). 
Aggrecan family of PGs consists of four PGs: aggrecan, versican, brevican and neurocan. All 
of those PG have hyaluronic acid binding domain at N-terminal, central region binding CS 
GAGs and C –terminal contain C-type lectin domain. Out of aggrecan family PGs, the best 
studied is aggrecan(Esko et al. 2014). 
Aggrecan is a 250 kDa PG with 2415 amino acid protein core. There are three isoforms and 
two known O-glycosylation sites (both probable) and nine known N-glycosylation sites (eight 
are potential). (Uniprot n.d.) It is reported that aggrecan have more than100 CS chains and 
20-30 keratan sulfate chains (Kjellen & Lindahl 1991) It is a major component of 
extracellular matrix in cartilage tissue and its function is to resist the compression of the 
cartilage. It is tissue specific and exists solely in a secreted form (Uniprot n.d.). 
1.1.10 The linkage region formation 
The synthesis of PGs begins at the ribosomes, in the ER, where the protein core of the future 
PG is being translated from mRNA.  O-glycosylation on serine residues in the early secretory 
pathway with a single xylose sugar starts the synthesis of GAG chain. The xylose sugar is 
attached to a serine next to a glycine by a xylosyltransferase enzyme- either XYLT1 or 
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XYLT2. Subsequently two galactose sugars are attached, in sequence, by the action of two 
galactosyltransferase enzymes: GalT-1 and GalT-2. The addition of a glucuronic acid (GlcA) 
moiety by GlcAT-1 transferase concludes the formation of the linkage or linker region 
(Kreuger & Kjellén 2012a). 
There are two types of modifications that can affect the linker region: phosphorylation of 
xylose sugar and sulfation of galactose sugars. It has been shown that these modifications can 
affect downstream enzymatic polymerization process. The result of intense modification of 
xylose and/or galactoses can be restriction or even inhibition of enzymes involved in 
synthesis of the linkage region. It is stipulated that 4-O-sulfation of the second galactose 
residue can be driving CS formation (Kreuger & Kjellén 2012a). In this respect, addition of 
the fifth sugar, the first N-acetylhexosamine is critical for selective assembly of CS or HS 
chains (Mikami & Kitagawa 2013). 
1.1.11 Synthesis of heparan sulfate (HS) 
Addition of the fifth moiety, the first sugar subsequent to the linker region is the deciding 
point in selection between heparan (N-acetylglucosamine) and chondroitin (N-
acetylgalactosamine) sulfate synthesis. The exact mechanism that rules this choice is still 
elusive. The “gagosome” model suggests a competition between different enzymes involved 
in GAG polymerization would result in either CS synthesis or HS synthesis (Dick et al. 
2012). 
HS polymerization is initiated by enzymes from the EXTL family of glycosyltransferases. 
Those enzymes attach N-acetylglucosamine (GlcNAc) to a non-reducing end of the 4
th
 
moiety on the linker. Enzymes EXTL -1, -2 and -3 have been shown to possess ability to 
transfer N-acetylglucosamine; therefore each one of them can be involved in HS-chain 
polymerization.  EXTL-3 seems to be the enzyme most involved in initiation of HS 
biosynthesis, but EXTL-2 and -1 are also necessary for proper HS biosynthesis. The 
increased level of EXTL-3 results in increased HS chain length which suggests a complex 
regulation of HS biosynthesis (Kreuger & Kjellén 2012a). EXTL-2 exhibits dual transferase 
activity. It can attach either GlcNAc or GalNAc to the tetrasaccharide linker region. Addition 
of GlcNAc will initiate HS biosynthesis whereas addition of GalNAc (by EXTL-2) is 
suggested to inhibit CS biosynthesis, as GalNAc does not serve as an acceptor for successive 
CS polymerization (Kreuger & Kjellén 2012a). 
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Following EXTL-mediated initiation, the HS chain is polymerized by a functional HS 
polymerase complex which is composed of EXT-1 and EXT-2. This complex transfers GlcA 
and GlcNAc sugars in alternative fashion onto growing chain.  The interaction between EXT-
2 and N-deacetylase/N-sulfotransferase 1 enzymes is implied in regulation of the HS chain 
length (Kreuger & Kjellén 2012a). 
1.1.12 Synthesis of Chondroitin sulfate (CS) 
The linker region synthesis is a common pathway for HS and CS, while the elongation and 
modification of HS and CS GAG chains is carried out by  different sets of enzymes, which 
also generally seem to be localized to different sub-regions of the Golgi apparatus (Prydz & 
Dalen 2000). 
The elongation of CS chains is mediated by an action of two distinct transferases that extend 
the GAG chain with alternating Glucuronic acid (GlcA) ( by GlcA Transferase II) and N-
acetylgalactosamine (GalNAc) ( by GalNAc Transferase II) residues, where the GalNAc is 
the first to be added to the linker region (Mikami & Kitagawa 2013). 
In recent years, six homologous glycosyltransferases that are indicated in CS synthesis have 
been cloned and characterized in vitro. Based on their enzymatic activity they have been 
termed chondroitin synthase -1 (ChSy-1), chondroitin synthase -2 (ChSy-1), chondroitin 
synthase-3 (ChSy-3), chondroitin polymerizing factor (ChPF), chondroitin GalNAc 
transferase-1 (ChGn-1) and chondroitin GalNAc transferase-2 (ChGn-2). ChSy-1, ChSy-2 
and ChSy-3 enzymes have dual glycosyltransferase activity (GlcAT-II and GalNAcT-II), but 
are incapable of synthesizing CS on their own. However, the co-expression of any two out of 
four proteins (ChSy-1, ChSy-2, ChSy-3 and ChPF) results in significant increase of GlcAT-II 
and GalNAcT-II activity. (2)  This leads to CS chain elongation where the chain length is 
dependent on the composition of synthesizing enzymes. In conclusion, CS polymerization 
can be achieved by enzyme complexes (chondroitin polymerases) that consist of multiple 
combinations of the four enzymes: ChSy-1, ChSy-2, ChSy-3 and ChPF (Mikami & Kitagawa 
2013).  
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Figure 2. Schematic representation of CS GAG; names of glycosyltransferases are given in 
white boxes (Mikami & Kitagawa 2013). 
The ChGn-2 and ChGn-2 enzymes have both GalNAcT-I and GalNAcT-II activities and thus 
are believed to be involved in CS chain backbone initiation and elongation steps. They are 
also needed for CS chain length regulation and/or regulation of the GAG numbers (Prydz & 
Dalen 2000). 
 
Figure 3 Overview of CS and HS biosynthesis(Sugahara & Kitagawa 2000). 
1.1.13 HS and CS synthesizing enzymes localize to the Golgi 
apparatus 
Enzymes needed for completion of HS PG synthesis are localized in cis -, and medial- Golgi 
cisternae. On the other hand, enzymes needed in biosynthesis of CS PG are localized to the 
trans-region of the Golgi apparatus(Prydz & Dalen 2000). 
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Figure 4. Localization of PG polymerizing enzymes in the Golgi apparatus; STs- 
sulfotransferases, GlcAT- glucuronic acid transferases, GT- galactosyltransferases, XT-
xylosyltransferase (Prydz & Dalen 2000). 
1.2 N-glycosylation 
N-glycosylation is present in all domains of life: bacteria, archea and eukaryotes.  It involves 
a process in which an oligosaccharide is attached via an N-glycosidic linkage to a side chain 
of an asparagine residue of a protein core. The attachment site is specified by a consensus 
sequence of N-X-S/T (Aebi 2013).  
A lipid-linked oligosaccharide (LLO) is first biosynthesized on dolichol (an isprenoid lipid), 
which acts as a carrier molecule.  The building blocks of LLOs are: mannose (Man), GalNAc 
and glucose (Glc). These are delivered as nucleotide-activated sugars to the site of synthesis.  
The biosynthesis of LLO is carried out by a group of glycosyltransferases that act in a 
sequential manner. The LLO biosynthesis starts at the cytoplasmic side of the ER membrane 
with addition of GlcNAc-P to Dol-P and formation of Dol-PP-GlcNAc. Subsequent reactions 
result in formation of Man5GlcNAc2 before the LLO is “flipped” to the lumenal side of the 
ER. The exact molecular mechanism and protein involved in LLO-flipping are still poorly 
understood (Aebi 2013).  
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1.3 The COG complex 
1.3.1 COG structure 
COG- is an acronym for conserved oligomeric Golgi-complex which was initially described 
by Daniel Ungar and his team in 2002 (Ungar et al. 2002), while working with yeast and 
mammalian cell lines on the low density lipoprotein receptor. This complex is a heteromer 
composed of 8 subunits (labelled 1-8), where units 1 to 4 compose lobe A and units 5 to 8 
compose lobe B (Ungar et al. 2002). It localizes peripherally to Golgi membranes. It was 
shown that COG subunits 2-4, 1/8 and 5-7 form stable entities which indicated that the COG 
complex is composed by two lobes with a bridge in form of COG1-COG8 structure (Ungar et 
al. 2006). 
 
Figure 5. Schematic diagram of the COG complex (Ungar et al. 2006). 
  
1.4 COG complex function.  
The best documented example of COG function is its indirect involvement in glycosylation 
processes where defects in COG lead to severe glycosylation-linked syndromes. According to 
Ungar et al, 2006, the majority of published data suggests that the COG complex is involved 
in retrograde trafficking within the Golgi apparatus and in endosome to Golgi transport.  
 INTRODUCTION 
 
12 
 
In order to understand a protein’s function, it is vital to establish its interactive partners. The 
COG complex is shown to have a number of those. SNAREs, proteins involved in membrane 
fusion, are shown to interact extensively with COG complex subunits. Secondly, small 
GTPases- Rabs, which localize to the Golgi apparatus and are thought to take part in 
trafficking, are indicated in the COG interaction scheme (Willett et al. 2013). Moreover, COP 
I proteins are shown to strongly interact with the COG complex. With the abovementioned 
three classes of proteins: SNAREs, Rabs and COP I, that are pivotal to protein transport in 
the Golgi apparatus, the COG complex shows strong indication of involvement in protein 
intra-Golgi trafficking (Ungar et al. 2006). Furthermore, interaction with COP I proteins 
suggest that the COG complex is involved in retrograde transport, rather than anterograde. 
Subsequent studies of the COG complex revealed that its involvement in retrograde transport 
is more than a suggestion. A study by Oka, T. et al. (2004) (Oka et al. 2004) indicated the 
presence of type II integral Golgi membrane proteins with reduced steady-state levels in 
CHO cells that lacked the COG 1 and COG 2 subunits. Those proteins were termed GEARs 
and are comprised of the following family members: 
 
Figure 6. List of GEAR-proteins (Ungar et al. 2006). 
The function of mannosidase II (an enzyme involved in glycosylation) as GEAR could 
explain the global glycosylation defects in COG1 and COG2 deficient cell lines. 
Zolov and Lupashin showed in 2005 that cells with silenced COG3 gene, accumulated 
vesicles that carried a number of Golgi proteins: v-SNAREs, GS15, GS28 and cis-Golgi 
glycoprotein GPP130 (Zolov & Lupashin 2005). Those vesicles were labelled COG-complex 
depended vesicles (CCD vesicles) and showed to incorporate at least three GEARs on their 
membranes. CCD vesicles showed retrograde transport activity (Ungar, 2006). Up to date, 
 INTRODUCTION 
 
13 
 
experimental data shows that the COG complex is most likely involved in retrograde Golgi 
transport. However, the exact mode of action is still not fully understood.  
Other tethering factors, that are present in the Golgi proximity and involved in vesicle 
tethering (i.e. TRAPP, GARP/VFT), share some similarity with the COG complex. All of 
them, including COG, seem to react with Rab and SNARE proteins. It is possible that the 
COG complex could be, in fact, a Rab effector protein (Ungar et al. 2006). 
The COG complex is also implied in a number of activities surrounding vesicle trafficking. 
The COG complex, at least in some cases, is shown to recruit and activate Rab GTPases. 
Moreover, COG is implemented in possible remodeling of actin near the plasma membrane, 
and, in formation of membrane-bridging SNARE complexes (Ungar et al. 2006). 
1.5 Congenital disorders of glycosylation 
(CDGs) 
Glycosylation is a crucial process in a eukaryotic cell, but like all processes, it can 
malfunction. Because of its complicated nature and involvement of many steps there are 
many steps that can become aberrant.  
Congenital disorders of glycosylation are a group of syndromes that affect glycosylation 
process in humans. The moieties that are affected by CDGs are mainly glycosylated proteins, 
but lipids can also be affected, in which case the glycosylation of protein or lipid is defective 
or reduced. 
The two main types of glycosylation: N- and O- linked glycosylation differ in many aspects. 
N-glycosylation is two –step (trimming and extension) that occurs at three different sites ( the 
cytoplasm, the ER lumen, and the Golgi lumen), while O-linked glycosylation has most of its 
assembly in the Golgi lumen.  The spatial arrangement of N-glycosylation in which 
oligosaccharides is transferred from a lipid-linked state in the ER lumen onto a protein gives 
CDG numeral nomenclature that divides this group into two sub-groups: CDG I and CDG II 
type.  
 
CDG I –type syndromes affect the oligosaccharide synthesis on dolichol (Dol) 
oligosaccharide carrier, before it is transported onto a protein, while CDG II-type in modern 
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nomenclature concerns all other glycosylation defects affecting N-glycosylation after proteins 
have been initially decorated with pre-synthesized glycan and all other defects affecting the 
synthesis of O-glycans and glycolipids.  
Until recently, glycosylation diseases were named using the CDG acronym followed by a 
sub-group number and a letter assigned alphabetically following a chronological order of the 
subsequent discovery. Currently, it is recommended to use genomic nomenclature in order to 
specify which gene(s) is the causative effect. Therefore it is recommended to put a mutated 
gene abbreviation along with the CDG acronym. 
However, even though nomenclature of glycosylation disorders has changed, two systems are 
still used.  
Within the CDG’s linked to N-glycosylation pattern, there are 15 identified defects- 12 from 
CDG I and 3 from CDG II sub-groups (Jaeken 2013). 
In the O-glycosylation pathway, defects have been found in the following biosynthesis 
pathways: O-xylosylglycans, O-N-aceltylgalactosaminoglycans, O-N 
acetylglucosaminoglycans, O-fucosylglycans and O-mannsylglycans. The glycosphingolipid 
and GPI glycosylation pathways have two syndromes described up to date: SIAT9-CDG and 
PIGM-CDG. There are numbers of glycosylation syndromes that affect multiple 
glycosylation and other pathways and in this group COG4-CDG, COG8-CDG and COG7-
CDG are described (among others) (Jaeken 2013). 
 
Figure 7 Comparison of different COG-CDGs. Glycosylation defects apply to N-glycosylation. (Reynders et al. 
2009) 
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Patient with COG4-CDG displayed seizures, dysmorphic facial features, mild ataxia and 
psychomotor development delay (Reynders et al. 2009). 
Patient with COG8-CDG showed seizures, failure to thrive, dysmorphism (small feet and 
hands), ataxia and neurological regression (Foulquier et al. 2007). 
 
1.5.1 COG7 mutation and COG7-CDG 
COG7-CDG was firstly described by Wu et al in 2004 (Wu et al. 2004), when two siblings 
(P1 and P2) with Mediterranean background were diagnosed with several severe clinical 
symptoms. Their parents were consanguineous, but otherwise healthy. Siblings displayed 
dysmorphia, mental retardation, general hypotonia and failure to thrive. Their lysosomal 
enzymes were elevated in their circulation and abnormal glycosylation of transferrin was 
observed. Moreover, significant reduction of sialic acid levels in serum led to a final 
diagnosis of a glycosylation defect - a CDG. Further diagnosis revealed that P1 had decreased 
sialylation, while P2 did not deviate from the normal pattern in this regard. Furthermore P1 
has shown defects in O-linked oligosaccharide synthesis that seemed to be a result of 
decreased activity of nucleotide sugar transporters as well as glycosyltransferases; cells from 
P2 did not show the same changes (Wu et al. 2004). 
These particular patterns in glycosylation defects lead the team to a discovery that P1 had 
mutation in its COG complex. The result was a homozygous intronic mutation (for both P1 
and P2) IVS+4 A →C. This allowed cryptic, conserved alternative splicing site near the 1st 
intron/exon boundary that resulted in 19-base deletion of COG7 mDNA. The COG7 protein 
level was reduced in both patients, due to reduced splicing efficiency, a premature 
termination codon or both.  P1 and P2 had the COG7 protein levels reduced by 95% and 85 
%, respectively, and COG7 mRNA reduction also followed those values. Introduction of wt-
cog7 DNA via molecular cloning could rescue glycosylation and trafficking properties in 
COG7 cells. Wu et al were the first to show a new class of CDG in which the affected gene is 
not directly involved in synthesis of complex glycans or synthesis or transport of sugar 
donors, but rather coding a protein involved in trafficking of the glycosylation machinery 
(Wu et al. 2004) 
..
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2 Materials and Methods 
2.1 Cell tissue culture 
Cells used in this project were made available by Dr Erik Eklund, Lund University. COG7, 
E42, and E12 were the names of the cell lines. E42and E12 were fibroblasts harvested from 
lower arm skin of healthy individuals and COG7 were fibroblasts harvested form neonatal 
patient that showed COG7-deficiency. 
All culture work was carried out using standard aseptic techniques, unless otherwise 
specified. 
1. Used complete medium and trypsin were always heated to 37°C before being applied 
to cell cultures, unless otherwise specified. 
2. Throughout most of the project E42 cells were used as control, or “healthy” cells. 
Unless otherwise specified, it should be assumed that E42 cells were used as a 
control. 
3. COG7 cells showed satisfactory cell growth initially, but after few months their 
growth rate deteriorated and cells stopped dividing. This resulted in limited amount of 
data obtained in the project. It is worth notifying that the patient form which the cells 
were obtained, deceased at age of 2 months. 
Standard incubation conditions: air-flow incubator; 5 % CO2 and 37°C 
2.1.1 Culturing cells from frozen samples 
The cells were obtained in medium from the University of Lund, multiplied by continuous 
culture and frozen down as ampules for later use. Upon thawing, the cells were grown in the 
cell lab according to the following procedure: 
1. Ampules were thawed in water bath at 37°C.  
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2. Thawed cell suspension was transferred aseptically into 20 ml of DMEM (complete 
medium), supplemented with 10 % fetal bovine serum (FBS) and 1 % 
Penicillin/Streptomycin in 75 cm
2
 cell culture flasks. 
3. Cells were cultured in an air incubator under 5 % CO2 and 37°C for 3 days. 
4. After 3 days, the growth progress was examined under the light microscope and if 
confluence was satisfactory, cells were passaged. If the confluence wasn’t 
satisfactory, the medium was changed and replaced with a new 20 ml and the cells 
were grown for another 3 days with daily checking of confluence. 
2.1.2 Cell passage 
Cell passage was performed in order to increase number of proliferating cells and increase 
their living space. Cell passage was only performed on fully confluent cell culture flasks. The 
procedure was carried out as follows: 
1. Old medium was removed from culture flask and cells were washed briefly with 5 ml 
of trypsin at 37°C, for 1-2 min. 
2. 5 ml trypsin was removed from the culture flasks and replaced with fresh 1.5 ml of 
trypsin. Cells were then incubated, with trypsin, for 30 min in an incubator at 37°C 
and 5 % CO2..  
3. After incubation, cells were checked to ensure full release from the culture flask. 
4. Trypsin was then quenched with 20 ml of complete medium and the total volume was 
spun down at 1500 rpm for 7 min. 
5. The supernatant was discarded and the pellet war re-suspended in 5 ml of complete 
medium. 2.5 ml of the cell suspension was transferred into fresh 20 ml complete 
medium in a new culture flask. This was repeated for the remaining 2.5 ml of the cell 
suspension. 
6. Two new flasks were then incubated in an air-incubator under 5 % CO2 and 37°C for 
3 days and the cell growth was investigated. 
 MATERIALS AND METHODS 
 
18 
 
2.1.3 Cell transfer to well plates (6 x 2 ml) 
In order to carry out metabolic labelling [section 2.2], cells were split and transferred into cell 
culture plates. The procedure was carried out as follows: 
1. Cells were trypsinated as per 2.1.2, points 1 to 3. 
2. Trypsin was quenched with 5 ml of complete medium and the solution was 
centrifuged for 7 min at 1500 rpm. 
3. The supernatant was discarded and the pellet was resuspended in a suitable volume of 
complete medium (2.0 ml per well, i.e. for 4 wells- 8.0 ml of complete medium). 
4. 2.0 ml of the cell suspension was transferred into each new well in a 6-well cell 
culture plate and incubated for 3 days at standard conditions. 
After 3 days, cells were observed under the light microscope to ensure proper adhesion and 
cell density. 
2.1.4 Cell tissue maintenance 
If the cells were not used in experiments, their complete medium was changed every 3 to 4 
days. Old medium was discarded and replaced with an equal amount of fresh complete 
medium. If the cells were completely confluent, the cells were passaged as per section 2.1.2. 
2.1.5 Freezing of cells 
Unused cells were frozen in order to increase their viability and create a working bank for 
later cell culture. 
The cell freezing procedure was carried out as follows: 
1. Cells were removed from cell culture flasks using trypsination [section 2.1.2, points 
1-3]. 
2. 5.0 ml of complete medium was added to the cell suspension in trypsin before 
centrifugation for 7 min at 1500 rpm. 
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3. The supernatant was discarded and the pellet was dissolved in 1.2 ml of freezing 
medium (Complete medium with 10 % dimethyl sulfoxide (DMSO)). 
4. The cells suspended in freezing medium were transferred to a cryoampule and 
labelled accordingly. 
The ampule was placed ASAP in -80 °C freezer for 24 hr. After 24 hr, the ampule was 
transferred to liquid nitrogen for long term storage. 
2.1.6 Harvest of non-radioactively labelled fractions (M and CL) 
Non-radioactively labelled medium (M) and cell lysate (CL) fractions were used for WB 
analysis [section 2.8] and protein concentration [section 2.12] for subsequent analysis. The 
harvesting procedure was carried out only with cell culture flasks that showed full 
confluence. Collected medium was serum-free, in order to exclude any proteins from sources 
other than the analysed cells. 
Harvest of non-radioactively labelled medium  
The harvest of M was carried out as follows: 
1. Old medium was removed from cell culture flask followed by two washings steps, 
each with 20 ml of DMEM without supplements. Used DMEM was discarded. 
2. New 20 ml of DMEM was added to culture flask and the cells were incubated for 30 
min in an incubator at 37°C, 5 % CO2. The medium was discarded and the cells were 
washed briefly once more in DMEM. 
3. The washing medium was replaced with 20 ml of fresh DMEM and incubated for 24 
hr under the same conditions (1
st
 incubation period). 
4. Medium was harvested, and replaced with 20 ml of another fresh DMEM for further 
24 hr (2
nd
 incubation period). The harvested Ms was labelled accordingly and frozen 
at -80 °C. 
After the 2
nd
 incubation period, the medium was collected again, labelled accordingly and 
frozen at -80°C. 
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Harvest of non-radioactively labelled CL 
1. Harvest of CLs was carried out immediately after the final medium harvest to achieve 
paired data sets. 
2. The harvest of CL was carried out as follows: 
3. After harvesting medium [section 2.1.4.1], cells were briefly washed three times with 
10 ml of ice-cold, sterile, 1x PBS (phosphate buffered saline). Washings were 
discarded. 
4. 5 ml of ice cold, sterile 1x PBS was added to the culture flask and the cells were 
scraped off from the bottom of the culture flasks, using a rubber policeman. The 
culture flasks were then inspected under the light microscope to ensure complete 
removal of attached cells. 
5. 5 ml of ice cold, sterile 1x PBS was added and additional cells were poured off and all 
cells removed were centrifuged for 7 min at 1500 rpm. The supernatant was 
discarded. 
6. The cell pellet was labelled accordingly and frozen at – 80 °C. 
When it was necessary to use CL fraction, frozen pellet was removed from freezer, thawed 
and lysed in 1.0 ml of lysing buffer for 20-30 min at room temperature. 
2.2 Metabolic labelling 
2.2.1 Substrate supply 
Metabolic labelling was carried out in order to provide cells with radioactive 
35
S-SO4
2-
. These 
sulfate ions would in turn be incorporated in sulfated GAG chains on PGs. When working 
with live cells, the aseptic procedure was put into place. Procedure for metabolic labelling 
was as follows: 
1. From 2.1.3, old complete medium was removed from each well in a 6-well cell 
culture plate and replaced with 1.5 ml of 
35
S-SO4
2-
 (0.2 mCi/ml) in RPMI-1640 
without sulfate. The medium also contained 2 % FBS. 
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2. Cells were incubated for 24 hr in an incubator at 5 % CO2 and 37°C. 
3. After 24 hr, the media and cell fractions were harvested 
2.2.2 Radioactively labelled CL and M harvest 
1.0 ml of harvested medium from radioactively labelled cells was applied to 4 ml G-50 fine 
Sephadex column and labelled macromolecules were eluted using 1.5 ml of dH2O.  
1. The elutes were collected, labelled accordingly (cell line name plus M) and frozen. 
2. Cell fractions remaining in wells were washed twice using ice cold PBS (2 x 2.0 ml) 
for 20 min, in order to prevent cross contamination from medium macromolecules. 
3. Washed cells were lysed by addition of 1.0 ml of ice cold lysis buffer and incubation 
for 40 min with shaking, on ice. 
4. CLs were collected and added to G-50 fine Sephadex columns and macromolecules 
were eluted following the same procedure as for the Ms. 
5. Elute was labelled accordingly (cell line name plus CL) and frozen at -20°C  
2.3 Scintillation counting  
Scintillation counting is a method used to determine radioactivity in a given sample. 
Radioactivity is measured by applying scintillation liquid to the samples to be measured. The 
scintillation liquid, upon exposure to radioactivity will emit light. This light emission is then 
measured by the scintillation counter and converted into counts per min (CPM). 
Scintillation counting was performed as follows: 
1. Appropriate sample volume was added to in scintillation count vials. 
2. Into each vial, 3.0 ml of scintillation fluid was added and the mixture was thoroughly 
mixed by inverting 5-10 times. 
3. Vials were placed in the scintillation counter racks and the appropriate measuring 
program was set up and executed, using manufacturer’s software. 
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4. Read out was collected in printed form and the data was transferred into an excel file. 
5. Used vials were discarded following the appropriate procedure.  
For analysing crude samples (CL and M), 40 μl of sample volume was used. For Gel size-
exclusion chromatography [section 2.7] 1.0 ml of sample volume was used. 
 
2.4 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is a method used for 
separation of protein molecules based on their molecular mass (Mw). Each molecule 
possesses more or less intrinsic electrostatic charge, which makes it attracted to the opposite 
charge and thus may move through a medium through which an electric current is applied. In 
SDS-PAGE, SDS is a detergent that gives uniform charge for all protein molecules after 
incubation at high temperature so each protein will ideally have the same mass-charge ratio, 
but not the same mass. The mass will determine the speed by which a protein would travel 
through the gel (polyacrylamide). The lighter proteins travel faster through the gel and the 
heavy proteins travel more slowly. Over fixed time period, the proteins will separate 
themselves on the basis of Mw. 
This procedure describes the SDS-PAGE analysis with gel drying, that subsequently lead to 
radiographic imaging. 
Into each gel a molecular marker was loaded (1-3 μl/well).SDS-PAGE analysis used for WB 
and silver stain imaging is described in section [section 2.8] 
The SDS-PAGE analysis was carried out as follows: 
1. Appropriate volume of sample (calculated beforehand) was dried in a freeze dryer in 
order to concentrate it. 
2. Concentrated samples were re-suspended with a calculated volume of a previously 
created master mix. 
3. Samples were heated for 3 min at 97°C, to allow proper denaturation of proteins. 
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4. Samples (maximum total volume of 40 μl) were loaded into the wells of a Criterion 
XT Precast Gel Bis-Tris 4-12 % along with molecular marker (1-3 μl). 
5. Gel was run for 80 min at 180 V, 180 mA. In some cases , increased time was applied 
in order to bring the protein front closer to the gel’s end, thus achieving better 
separation.  
6. The gel was removed from SDS-PAGE running buffer, washed twice with dH2O, and 
put into t fix solution overnight, with rocking (minimal time needed for fixation is 1 
hour, recommended overnight).  
7. After fixation, fix solution was discarded following the standard procedure. Gel was 
washed twice with dH2O and amplified with Amplify solution (GE Healthcare) for 30 
min. 
8. Following amplification, gels were washed twice with dH2O and placed on a slob gel 
dryer at 80°C until dry. Filter paper was placed under the gel to prevent contamination 
and plastic foil was placed on top for protection. 
9. Dry gels were then removed and processed for radiographic imaging 
2.5 Radiographic imaging 
 
Radioactive atoms emit energy as radiation, eitherα-particles or β- or γ- rays. The exact 
energy and nature of radiation is specific for each radioactive element. In this project, the 
radioactive sulfur isotope, 
35
S, was used in the form of sulfate ions 
35
S-SO4
2-
. Radioactively 
labelled PGs [section 2.2] incorporate radioactive sulfate during synthesis and may be 
visualised after separation on SDS-PAGE gels. 
The radiographic imaging was carried out in a PhosphoImager as follows: 
1. Previously dried gels [section 2.4] are placed in an exposure cassette for overnight 
exposure. One must take care to make sure that the gel is properly dried; any traces of 
water would damage the cassette and distort the results. 
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2. Exposure screen was placed on a Typhoon PhosphoImager for gel imaging. The 
Typhoon Reader should be turned on at least 30 min before taking the image for 
better results. 
3. Using software (Typhoon scanner control 3.0), a gel image was taken at 200 
pixels/micron resolution. The file was saved on external memory for further analysis. 
4. Used exposure cassette was erased using image eraser equipment. 
 
2.6 Enzymatic digestion of GAGs  
Enzymes that can digest HS or CS were used to determine the characteristics of PGs present 
in the sample. Hep digests HS, leaving CS and other GAGs, while chondroitinase ABC 
(cABC) digests chondroitin and dermatan sulfate, leaving HS and other GAGs undigested. 
2.6.1 cABC digestion 
cABC, E.C. 4.2.2.4, is an enzyme that catalyses the eliminative cleavage of N-
acetylhexosaminide linkages in CS A, CS B, CS C, chondroitin, dermatan sulfate and 
hyaluronic acid yielding mainly disaccharides (Amsbio n.d.). The yielded disaccharides will 
travel through an SDS-PAGE gel and will not be seen as a band on a radiographic gel image 
of 
35
S-labelled macromolecules. The remaining bands would mostly represent HS PGs and to 
some extent other sulfated molecules. 
The digestion with cABC enzyme was carried out as follows: 
 
1. An appropriate volume of samples (8-40 μl) was transferred into 1.5 ml Eppendorf 
tubes and dried in the freeze dryer. 
2. Fully dried samples were re-suspended in 15 μl of 1x cABC buffer. 
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3. 30 mU of cABC enzyme was added to each re-suspended sample and incubated for 
1hour at 37°C in a heating block. For control samples, 5 μl of 1x cABC buffer was 
added instead of cABC enzyme. 
4. Digestion was stopped after 1 hour with 2 min of heating at 97 °C. The samples were 
then either applied to SDS-PAGE gel analysis [section 2.4] with radiographic imaging 
[section 2.5], or in the size-exclusion gel column chromatography [section 2.7]. 
 
2.6.2 Heparinase I, II, III (Hep) enzymatic digestion   
Heparinase I, II, III, (Hep) E.C. 4.2.2.8, is an enzyme mix that cleaves selectively, via an 
elimination mechanism, sulfated polysaccharide chains containing 1-4 linkages between 
hexosamines and glucuronic acid residues. It cleaves HS solely and does not cleave 
fractioned heparin or low Mw heparin (IBEX Pharmaceuticals 2011). The saccharide that is 
yielded in the reaction would, similarly to cABC digestion, travel through gel and the bands 
remaining will be CS PGs and other sulfated molecules. 
 
The digestion with Hep was carried out as follows: 
1. An appropriate sample volume (8-40 μl) was dried using a freeze dryer. 
2. Dried pellet was re-suspended in 15 μl of 1x Hep buffer. 
3. 0.1 mU of Hep enzyme was added to the re-suspended sample. 
4. The sample was mixed and incubated for 16 hr at 28°C on a heating block. 
Digestion was stopped after 16 hr with 2 min incubation at 97 °C. The samples were either 
subjected to SDS-PAGE gel analysis [section 2.4] with radiographic imaging [section 2.5] or 
to gel filtration chromatography [section 2.7]. 
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2.7 Size exclusion gel chromatography  
Size exclusion gel chromatography separates molecules based on their Mw. In size exclusion 
chromatography, the columns are filled with beads that contain pores of a defined size. 
Molecules larger than the pore will be excluded from entering the beads and travel fast 
through the column and elute in V0 (void volume), while molecules that fit in the pore will 
also travel through the beads and will elute later, at Vt (total volume) if the molecules have 
full access to the internal volume of the bead material. In this project, radioactively labelled 
PGs were analysed by size-exclusion gel chromatography. In theory, PGs with full GAG 
chain modification would elute in V0, and small molecules (i.e. disaccharides) would elute in 
Vt.  
Gel material used was CL6-B Sepharose ™; plastic column was 1x40 cm, gel volume was 40 
ml. Samples for column chromatography were previously metabolically labelled [section 2.2] 
and enzymatically digested [section 2.6].  
 
The size exclusion gel chromatography was carried out with the following steps 
1. Obtained sample was supplemented with 150 μl of blue dextran/potassium dichromate 
solution or more to avoid too much dilution. This solution provided molecular size 
markers for V0  (blue dextran- blue colour) and Vt (potassium dichromate-yellow 
colour). 
2. Columns were purged with running buffer at 0.14 ml/min flow rate for 30 min. 
Columns were then equilibrated with running buffer at a flow rate of 0.14 ml/min. 
3. Sample was applied dropwise onto the column, allowed to sink into the column 
material and overlayered with running buffer. 
4. Fractions were collected at 7 min/fraction. Collection started when the blue marker 
had approached the end of the column. For each run, 40 fractions were collected 
directly into scintillation vials. 
5. After collection was completed, each fraction was supplemented with 3.0 ml of 
scintillation liquid. Fractions with strong blue and yellow colour were marked as V0 
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and Vt. Subsequently, the radioactivity in each fraction was determined in a 
scintillation counter and the data was recorded in an excel file. V0 and Vt fractions 
were marked accordingly. 
2.8 Western blotting (WB) 
In WB, proteins that have been separated on SDS-PAGE gels are transferred to a membrane. 
This allows for subsequent incubation with antibodies that will detect the presence of specific 
proteins. WB is used to detect and quantify proteins of interest, although the quantitation may 
be regarded as semi-quantitative. 
The WB was performed in this project using NuPAGE 4-12 % Bis-Tris gels, in contrast to 
SDS-PAGE gels used in radioactive imaging (Criterion XT). 
Through this project only the wet transfer method was used. 
The WB was carried out as follows: 
1. An appropriate, calculated, volume of each sample (2-16 μl) was mixed with 
NuPAGE master mix, in order to achieve a satisfactory dilution level. 
2. Samples were heated at 70°C for 10 min on a heating block. 
3. Gel was run, following the manufacturer’s suggestion, at 120 V for 120 min. 
4. Transfer of the proteins to a PVDF membrane was carried out using the 
manufacturer’s manual, at 30 V and 180 mA for 1 hour. 
5. The membrane was then blocked with 2 % ECL Blocking agent in 1x TTBS at 
4°C, overnight. 
6. After blocking, the membrane was blotted with the primary antibody (1st Ab) 
solution at 4°C for overnight. The recommended dilution of each antibody was 
obtained from the supplier’s records (between 1:2000 and1:5000).   
7. After primary antibody incubation, the membrane was washed 5 times for 10 min, 
each time with fresh 1x TTBS. 
8. After washing steps, membrane was blotted with a secondary antibody (2nd Ab) 
solution for 1 hour at room temperature.  The dilution used was 1:50 000. 
9. The membrane was then washed 5 times for 10 min, each time with fresh 1 x 
TTBS 
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10. The membrane was then incubated with ECL™ Detection reagent using 
Amersham ECL ™ Select WB Detection reagent manufacturer’s manual. For each 
membrane 1.0 ml to 1.5 ml of the final development solution was used. 
2.8.1 WB imaging 
Imaging of WB membranes was carried out on a Kodak Image Station 400R Pro using 
luminescence settings and the exposure time was 1-5 min. Files were saved on an external 
drive. Methods for taking images followed the manufacturer’s manual. 
 
2.9 Dialysis and concentration of Ms 
Ms from E42 and COG7 were dialysed and concentrated to achieve a high protein 
concentration required for WB analysis. This was carried out due to the fact that PGs are 
expressed at low levels in cells when compared with more abundant proteins. 
Dialysis was only performed on non-radioactively labelled harvested Ms [section 2.1.6] from 
E42 and COG7 cells. 
 
The dialysis of Ms was carried out as follows: 
1. 5.0 ml of harvested medium was placed in a dialysis cassette. 
2. The cassette was placed in 3 litres of dH2O with stirring overnight at 4°C. 
3. Dialysed medium was removed from the cassette and placed in a centrifugal filter 
tube for concentration. 
4. The tube was centrifuged at maximum rpm (in Alexa X-22 centrifuge) for 40 min 
or until the un-filtrated medium reached 1.0 ml in volume  
5. Un-filtrated liquid was transferred into 5 Eppendorf’s tube, 200 μl in each. The 
tubes were labelled and placed in freeze dryer and dried. 
6. The tubes were dried until there was no liquid present and/or a precipitate formed. 
Then the tubes were removed from the freeze dryer and either the precipitate was 
frozen at -20°C for future work or it was re-suspended with 20 μl of appropriate 
solvent (dH2O or buffer).  
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2.10 Ion-exchange chromatography 
Ion-exchange chromatography separates molecules on the basis of their affinity to ligand on 
the column, which is either positively or negatively charged. In theory, all PGs, since they 
have negatively charged GAGs chains, should bind to a positively charged column and would 
not elute until displaced by ions with higher affinity. In this project 2 x 5 cm plastic columns 
were used with a DEAE-sephacel gel volume of 1.0 ml. 
All steps were carried out in the cold room at 4-8°C.  
The ion-exchange chromatography was carried out as follows: 
1. A 2 x 5 cm plastic column was filled with 1.0 ml of DEAE-sephacel column 
material and was equilibrated with 6.0 ml of buffer A. Flow rate was established at 
3-5 seconds/drop. 
2. Sample was applied (5.0 ml of dialysed, but not concentrated medium) at 5-10 
seconds/drop. The flow-through was collected and labelled Elute 1. 
3. The column was washed with buffer A twice with 5.0 ml each time at elution rate of 
3-5 seconds/drop. Elute was collected as “Elute 1.2” and “Elute 1.3”. 
4. 5.0 ml of buffer B was applied to the column and the elute was collected as “Elute 
2” with rate of 5-10 seconds/drop. 
5. 5.0 ml of buffer B was applied to the column and the elute was collected as “Elute 
3” with rate of 5-10 seconds/drop. 
6. The column was washed with 2 x 5.0 ml of buffer A, capped and stored at 4°C. 
Elutes 1.2 and 1.3 were eventually discarded as these low-salt washes do not contain any PGs 
of interest. Elutes 1and 2 were analysed by mass spectrometry to establish the presence of 
PGs. Elutes 1 and 2 were also analysed by SDS-PAGE followed by silver staining to 
visualize proteins. 
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2.11 Mass Spectrometry (MS) 
Mass spectrometry is a powerful tool used to identify proteins and protein modifications 
based on their mass to charge ratio (m/z ratio). In this project, MS was used to identify 
potential PGs and their modifications from COG7 and E42 M samples. 
Procedure: 
The samples submitted for analysis were derived from Elute 1 and 2 obtained during ion –
exchange chromatography. 
All MS analysis was carried out by Anders Moen, the Head Engineer in mass spectroscopy 
facility at Department of Biosciences, University of Oslo. Peptide search and identification 
was carried out by Anders Moen. 
2.12 Protein measurement- BCA™ Assay 
This method is based on reduction of copper ions (from Cu
2+
 to Cu
+
) by protein in an alkaline 
solution. Highly sensitive and selective colorimetric detection is connected to the reduction 
reaction by a unique reagent based on bicinchoninc acid. The detection is carried out at 562 
nm and may be read in the spectrophotometer. 
The procedure was carried out according to manufacturer’s manual (BCA™ Protein Assay 
Kit, 23225, 23227, Pierce, Rockford, IL) with minor deviations, listed below: 
1. BSA standards were prepared using DMEM instead of dH2O for measuring protein 
concentration in the medium. 
2. BSA standards were prepared using lysis buffer instead of dH2O for measuring 
protein concentration in CLs. 
3. The sample working dilution was 1:20 at all times. 
4. Incubation took place in an air incubator. 
5. Before each read in  spectrophotometric plate reader, the plate was shaken for 5 
seconds and left to settle for 10 seconds 
6. Readouts were printed and transferred into an excel file. 
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2.13 Silver staining 
 
Silver staining is a sensitive method to detect proteins in an SDS-PAGE gel. It utilizes silver 
nitrate which binds to selective amino acids in proteins at neutral or weakly alkaline pH. The 
protein bound silver ions are reduced by formaldehyde at alkaline pH to form metallic silver 
in the gel. The proteins are visualized as dark bands in the gel. 
Procedure: 
Silver staining was carried out according to manufacturer’s manual (Sigma, ProteoSilver™ 
Plus Silver Stain Kit, Product code: PROT-SIL2) with a development time of 4.5 min. 
2.14 Radiographic gel quantification 
Bands obtained from radiographic imaging were quantified and analyzed using ImageQuant 
™ software using the software manufacturer’s procedure. Mathematical analysis was carried 
out in Microsoft Excel 2010 using data obtained from ImageQuant™ steps. This data should 
be treated with caution, as only a limited number of samples were analyzed and thus 
statistical analysis could not be performed.  
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3 Results 
3.1 Overview of the work 
 
Figure 8. Overview of the work carried out 
Aim of this project was to characterize PGs synthesized by COG7 deficient (throughout this 
document referred as COG7) cells. As of May 2014, scientific literature did not cover this 
area of research. The initial hypothesis was that PG synthesis is altered in COG7 cells. 
Throughout the project two control cell lines were available, entitled: E42 and E12. These 
cell lines were dermal fibroblasts collected from the lower arm of two healthy human 
individuals and should, in theory, provide representative sample of wild-type PG expression. 
However, some heterogeneity was observed during the initial experimental stage, and from 
that moment on E42 cell line was used as a control, but some data came from E12 cells were 
also generated. Within this document control refers to the E42 cell line, unless otherwise 
stated. 
One can divide proteins into two major fractions according to their localization: cellular and 
secreted. In this project, samples of PGs have been divided accordingly into these two 
fractions: cell lysate (CL) and medium (M). The medium in which the cells have grown and 
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to witch proteins and PGs are secreted is labelled medium, M, and cell lysate is labelled CL. 
Control (CTR) refers to two instances:  
1. A “normal” cell line (E42) and  
2. Non-enzymatically treated sample.  
3.2 Metabolic labelling 
3.2.1 Introduction 
In order to determine if in fact PG synthesis is aberrant in COG7 cells, metabolic labelling 
with radioactive sulfate was initially performed. This means that radioactively labelled 
35
S-
SO4
2-
 sulfate is fed to cells and gets incorporated during sulfation modification in the GAG 
chains of PGs. Since most of the sulfate is used in GAG chain modification (a smaller 
fraction of the sulfate is used in other ways), one can assume that this radioactive sulfate will 
label mainly PGs. However, when it comes to quantitative description of sulfate –labelled 
PGs, one has to take into account that the sulfate-labelling level does not correspond directly 
to the sulfation density on the GAG chain. Increased amounts of sulfate could also relate to 
longer GAGs, increased number of GAGs and, of course, to increased expression of PG 
protein cores. 
 
Figure 9 
35
S-SO4
2-
 incorporation levels for COG4, COG7, COG8 and E42 cell lines. Cells were radioactively 
labelled for 24 hr. M and CL fractions were collected as per section 2.2.2and the unincorporated 
35
S-SO4
2
 ions 
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were removed by G-50 fine columns and the samples were measured via scintillation counting. Each sample 
contains equal volume (30 μl) of M and CLfraction  
It is clear that COG7 cells incorporate significantly more 
35
S-SO4
2 
in the secreted PGs than 
E42, COG4 or COG7 cells. The interesting feature in COG7 cells is increased incorporation 
when compared to other COG-mutants (COG4 and COG8) suggesting that increased 
sulfation of secreted PGs is a COG mutation specific. The difference in sulfation level was 
only observed in secreted COG7 PGs, where the COG7 CL fraction did not differ 
significantly from E42 and other COG mutants (COG4 and COG8) 
3.2.2 Metabolic labelling with 35S-sulfate- overview  
 
Figure 10. Overview of secreted PGs in E42, COG8, COG7 and COG4 cells. Cells were grown in 2 ml plastic 
wells with 
35
S-SO4
2-
 RPMI 1640 medium with dose of 0.2 mCi/ml for 24 hr. Medium was harvested according 
to section 2.2.2 and loaded onto SDS-PAGE gel with sample size of 30μl in each of the wells. Gel image was 
taken using PhosphoImager at 200 pixels per micron.  
Figure 10 shows clearly that there is extensive diversity between control and COG7 cell lines 
with respect to PG synthesis. In addition, also COG8 and COG4 cell lines showed deviation 
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form wild-type.  The control cell line (E42 M) showed heterogeneity in its secreted PGs, 
while, in contrast, COG7 showed comparative homogeneity.  It is clear that the most 
highlighted feature of COG7’s secretion profile is very high Mw PGs. COG4 and COG8 show 
strong bands at approximately 60-70 kDa. Those bands are also present in E42, but to a lesser 
intensity and with slightly modified Mw. 
 
Figure 11. Overview of PGs in CL from E42, COG8, COG7 and COG4. Cells were grown in 2 ml plastic wells 
with 
35
S-SO4
2-
 RPMI 1640 medium with dose of 0.2 mCi/ml for 24 hr. Medium was harvested according to 
section 2.2.2 and loaded onto SDS-PAGE gel with sample size of 30μl in each of the wells. Gel image was 
taken using PhosphoImager at 200 pixels per micron. The symbol “-“indicates an empty well.  
Figure 11 shows that in CLs, changes in PG synthesis are also present in COG7 cells when 
compared to control cell lines. It is clear that a predominant feature of COG7 CL PGs is their 
high Mw.  A high molecular mass band of strong intensity does not appear in COG8, COG4 
or E42 cell lines and thus appears to be specific to COG7 cells. All cell lines show bands at 
approximately 100 kDa, albeit with different signal intensities. E42 cells show the highest 
intensity in this band, whereas COG8 shows the lowest. COG4 and COG7 show similar 
intensity. COG7 CL lanes are the only ones that do not have bands at approximately 60 kDa, 
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with E42, COG8 and COG4 showing weak bands at this position. Similar bands are shown in 
Figure 10.  
3.2.3 Enzymatic degradation of GAG chains 
 
Figure 12. Enzymatic digestion E42, COG4, COG7 and COG8 M with Hep and cABC. Radioactively labelled 
Ms were digested with Hep and cABC as per section 2.6. CTR is control, where 1x cABC buffer was used 
instead of cABC. Total sample size of 30 μl was loaded onto each well in the SDS-PAGE gel and the image was 
taken using PhosphoImager at 200 pixels per micron. 
This figure shows a significant difference between wild type cells and COG-deficient cell 
lines. Although all shown COG-deficient samples showed aberrant digestion, COG7 exhibits 
an unusual pattern, when compared to COG4 and COG8. 
The most prominent feature of this enzymatic digestion is the dominating presence of CS in 
all of the COG-deficient cell lines. This is characterized by the presence of strong bands in 
the Hep lanes (COG4 M Hep, COG7 M Hep and COG8 M Hep) and complete disappearance 
of bands in the cABC lanes (COG4 M cABC, COG7 M cABC and COG8 M cABC). 
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Moreover, there is weak presence of HS in all of the COG-cells. Weak bands in the cABC 
lanes show remaining HS left after cABC digestion. Control cell lines showed greater 
proportion of HS in their secreted PGs. This is visualized by lesser reduction of signals in 
E42 M Hep and E42 M cABC lanes.  
 
Figure 13.  Enzymatic digestion of E12, E42 and COG 7 M & CL with Hep. Radioactively labelled Ms and CLs 
were digested with Hep as per section 2.6.2. CTR is control, where 1x Hep buffer was used instead of Hep. 
Total sample size of 30 μl was loaded onto each well in SDS-PAGE gel and the image was taken using 
PhosphoImager at 200 pixels/micron. The symbol “-“indicates empty well.  
It is clear that a significant fraction of cellular PGs from COG7 cells have HS 
glycosaminoglycan chain modification. Moreover, this HS modified PG has a lower 
molecular mass than the CS-modified PG that remains as a strong band at the top of the gel. 
Figure 13 shows also difference between cellular PGs from control cells (E12 CTR, E42 
CTR) and COG7 cells (COG7 CL). 
PGs from the CL of control cells showed almost complete modifications with HS, as there are 
only weak bands present in the lanes E12 CL Hep and E42 CL Hep. One could speculate that 
 RESULTS 
 
38 
 
there possibly could be the same band in E12 CL lane as in E42 CL Hep lane (approximately 
70 kDa) , but lower sulfation or lower PG expression could make the signal in E12 CL Hep 
undetectable. 
3.2.4 Enzymatic digestion quantification from gel images 
Gel images were quantified using Image Quant™ software.  
 
Figure 14. HS and CS composition of CL PGs from E42 and COG7 cells. Figure 13was quantified using 
ImageQuant™ software and the results were visualized by the above column chart. The difference between total 
signal value from CTR lane and total signal from Hep digest lane was expressed as a percentage of CS. The 
difference between total signal value from CTR lane and total signal from cABC digest lane was expressed as a 
percentage of HS. 
 
Figure 15. HS and CS composition of M PGs from E42 and COG7 cells. Figure 12  was quantified using 
ImageQuant™ software and the results were visualized by the above column chart. The difference between total 
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signal value from CTR lane and total signal from Hep digest lane was expressed as a percentage of CS. The 
difference between total signal value from CTR lane and total signal from cABC digest lane was expressed as a 
percentage of HS. 
Figure 14 and Figure 15 show the composition of GAGs in the COG7 and E42 M and CL 
fractions. It is clear that the majority of PG modification in COG7 M is of CS nature. 
Moreover, the HS composition in the CL varies between COG7 and the control cell lines. 
From this one may assume that COG7 cells have distorted both cellular and secreted PGs 
with respect to the HS/CS percentage composition. It is difficult to comment on the absolute 
level of HS or CS synthesis in COG7 and E42 cells due to significantly higher sulfate 
incorporation in COG7 cells. It is not clear what the HS synthesis level is in COG7 cells 
when compared to the E42 cells. 
3.3 Size –exclusion gel filtration chromatography 
Gel filtration chromatography is a powerful analytical tool used to describe molecular masses 
of macromolecules in the analyte. In all chromatograms, the x-axis describes the fraction 
coefficient and y-axis shows the percentage of the strongest (most intensive) peak. 
Fraction coefficient is a dimensionless number that is directly related to a fraction number. 
Fraction coefficient of 0 is equal to elution time of blue dextran (void volume, V0) and 
fraction coefficient of 1 is equal to elution time of potassium dichromate (K2Cr2O2) which 
will indicate the terminal volume where all molecules applied have been eluted, Vt. 
In theory moieties that are bigger than 200 kDa would elute at V0, along with blue dextran, 
which is a saccharide (polymer of anhydroglucose) with blue colour and high molecular mass 
(>200kDa). When it comes to PG analysis, the molecules eluted in V0 are high- Mw PGs (e.g. 
aggrecan core protein – 250 kDa) or medium to low Mw PGs with extensive 
glycosaminoglycan chain modification. It is important to notice that GAG chains could 
contribute largely to the overall PG mass, not only by the length of the polymer itself, but 
also by the sheer number of GAG chains attached to the core protein. 
As the harvested samples showed different levels of radioactive sulfate incorporation, the 
direct measurements of radioactivity deviated significantly. To counteract this, a 
normalization of peaks was performed in which the data was shown as percentage of the 
highest observed value. In this case, peaks can be compared with greater ease and conclusive 
remarks could be drawn. In all cases, the highest peak was present either at V0 or at Vt.  
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Figure 16. Gel filtration chromatogram of 
35
S-labelled E42 M with or without digestion with cABC or Hep. 
Radioactively labelled and harvested M was digested with cABC and Hep as per section 2.6. Sample was eluted 
in CL-6B column with blue dextran/potassium dichromate markers for Vo and Vt respectively Sample loaded 
was equal to 30 000 cpm. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
Figure 16 shows the natural expression of sulfated PGs in human skin fibroblasts, compared 
with enzymatically treated samples.  Judging the profile of E42 M cABC (red line), one can 
notice that there is small red peak at V0- this peak corresponds to undigested HS PG.  
Similarly, one should take notice on the blue line- E42 M Hep. The blue peak at V0 represents 
the undigested CS PG. It is clear, that the majority modification on the secreted PGs in the 
E42 cells is CS, but the presence of HS is significant. 
The two peaks that are present in the control sample, at fraction coefficient 0 and 0.45, 
describe two different PGs with different molecular masses. It is clear that both of those 
peaks contain heparan and CS modified PGs. It seems that the larger PGs (peak at fraction 
coefficient of 0) have been mostly modified with CS and to a smaller extent with HS. The 
second peak represents PG(s) that are possibly with a higher share of HS GAGs.  
0.00
20.00
40.00
60.00
80.00
100.00
120.00
-0.2 0 0.2 0.4 0.6 0.8 1 1.2 1.4
%
 o
f 
th
e
 m
o
st
 in
te
n
se
 p
e
ak
 
Fraction Coef 
E42 M Digest 
E42 M cABC
E42 M Hep
E42 M CTR
 RESULTS 
 
41 
 
 
Figure 17. Gel filtration chromatogram of 
35
S-labelled COG7 M after digestion with cABC or Hep. 
Radioactively labelled and harvested M was digested with cABC and Hep as per section 2.6. Sample was eluted 
in CL-6B column with blue dextran/potassium dichromate markers for Vo and Vt respectively Sample loaded 
was equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
Figure 17 shows the expression of secreted PGs from COG7 cells. It is clear that the majority 
of the PGs in the M are of CS nature. The unchanged peak profile at V0 in the COG7 M Hep 
line suggests a large quantity of CS. Additionally, the high peak at Vt from COG7 M cABC 
confirms this finding. A minor peak at Vt from COG7 M Hep suggests that there is some HS 
modification of PGs, but the level is very low.  
Both Figure 16 and Figure 17 support the main findings in the SDS-PAGE gel images and 
their quantification   for the M fractions (Figure 15). It is clear that CS is mostly (95%) 
present on secreted PGs in COG7 cells, while control cells show a more balanced HS/CS 
composition. 
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Figure 18. Gel filtration chromatograph of 
35
S-labelled E42 CL digestion with cABC and Hep Radioactively 
labelled and harvested CL was digested with cABC and Hep as per section 2.6. Sample was eluted in CL-6B 
column with blue dextran/potassium dichromate markers for Vo and Vt respectively Sample loaded was equal to 
30 000 cpm. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
In Figure 18, it is shown that PGs present in E42 CLs possess both types of 
glycosaminoglycan chains: chondroitin and HS. The CS modification is present, but to a 
much lesser degree than HS modification. The peak at fraction coefficient of 0.60 is shifted to 
0.40 after cABC digest. This suggests that this low Mw PG is modified with CS. However, 
almost complete digestion with Hep suggests that in fact, HS is the dominating modification. 
It is clear that the amount of HS is higher than CS. This data corresponds to Figure 13, in 
which Hep would degrade almost the entire HS from the sample and to Figure 14 where HS 
comprises approximately 85% of the GAGs modifications in the E42 CL. 
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Figure 19. Gel filtration chromatograph of 
35
S-labelled COG7 CL digestion with cABC and Hep. Radioactively 
labelled and harvested CL was digested with cABC and Hep as per section 2.6. Sample was eluted in CL-6B 
column with blue dextran/potassium dichromate markers for Vo and Vt respectively Sample loaded was equal to 
30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml 
Figure 19 shows the presence of both CS and HS in COG7 CLs. It is possible that the amount 
of CS is higher than HS, but it is speculative, especially in the light of Figure 14. It is, 
however, clear that both HS and CS are present as significant fractions of the GAGs of 
cellular PGs. 
 
Figure 20. Overview of secreted PGs in COG7 and E42 cell lines. Radioactively labelled and harvested Ms were 
eluted through CL-6B column with blue dextran/potassium dichromate markers for Vt and V0 respectively. 
Samples loaded were equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
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Figure 20 shows that secreted PGs from COG7 cells show immense, uniform destitution in 
weight, with the molecular mass of them averaging around 200 kDa which is the Mw of blue 
dextran. (Sigma Aldrich n.d.) On the other hand, the expression profile of the E42 cells 
shows three characteristic peaks at fraction coefficient of: 0, 0.4 and 1. The presence of peak 
at fraction coefficient of 1 suggests presence of small sulfated moieties in the M of E42. 
Those sulfated moieties are possibly sulfated disaccharides (GlcNAc/GalNAc-GlcA) either 
excreted from the cells or shed from the glycocalyx. There is no corresponding peak in COG7 
M. 
 
Figure 21. Overview of cellular PGs in COG7 and E42 cell lines. Radioactively labelled and harvested CLs 
were eluted through CL-6B column with blue dextran/potassium dichromate markers for Vt and V0 respectively. 
Samples loaded were equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
Cellular PGs overview differs significantly from the M spectrum in both COG7 and E42 cell 
lines.  
In the COG7 cell line, the cellular PGs show high heterogeneity in mass which is represented 
by the numerous peaks at different fraction coefficients (Figure 21, blue line). Peaks present 
after fraction coefficient of 1.0 are peculiar and those could either be an experimental 
contamination, background noise or non-incorporated 
35
S-sulfate. Multiple different peaks 
suggest PGs with different Mws. This corresponds to Figure 11 where second band showed 
similar weight distribution to the control cell line.  
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E42 cellular PGs show a pattern more similar to its secreted counterpart, but with some 
differences. 
 
Figure 22. Gel filtration chromatograph of 
35
S-labelled COG7 M and E42 M digestion with cABC. 
Radioactively labelled and harvested Ms were digested with cABC as per section 2.6.1. Sample was eluted in 
CL-6B column with blue dextran/potassium dichromate markers for Vo and Vt respectively Samples loaded 
were equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
It is clear that secreted PGs from healthy and COG7 cells show different modification 
patterns. Secreted COG7 PGs are almost entirely modified with CS. There are very little, if 
any, HS modifications. On the other hand, E42 produce significant amounts of HS, although 
the majority of modification comes from CS. This data follows Figure 15. 
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Figure 23. Gel filtration chromatograph of 
35
S-labelled COG7 CL and E42 CL digestion with cABC. 
Radioactively labelled and harvested CLs were digested with cABC as per section 2.6.1. Sample was eluted in 
CL-6B column with blue dextran/potassium dichromate markers for Vo and Vt respectively Samples loaded 
were equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
It is clear that both E42 and COG7 cells have CS modification present on their cellular PGs. 
However, the extent of which CS modifies PGs in E42 CL is lower when compared to COG7 
CL. This follows Figure 14. Cellular PGs show different cABC digestion profile, when 
compared to secreted PGs. However, the magnitude of the difference is greater among E42 
cells. Secondly cellular PGs of healthy cells have significant HS modification on them. 
Compared to their secreted PGs, cellular PGs of COG7 show higher extent of modification 
with HS. 
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Figure 24. Gel filtration chromatograph of 
35
S-labelled COG7 M and E42 M digestion with Hep. Radioactively 
labelled and harvested Ms were digested with Hep as per section 2.6.2. Sample was eluted in CL-6B column 
with blue dextran/potassium dichromate markers for Vo and Vt respectively Samples loaded were equal to 30μl. 
Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
Figure 24 corresponds to Figure 22 with respect to characterization of PG modification in 
Ms. It shows that there is very little HS on COG7 PGs and that the majority of secreted 
COG7 PGs are modified with CS. 
 
Figure 25. Gel filtration chromatograph of 35S-labelled COG7 CL and E42 CL digestion with Hep. 
Radioactively labelled and harvested Ms were digested with Hep as per section 2.6.2. Sample was eluted in CL-
6B column with blue dextran/potassium dichromate markers for Vo and Vt respectively Samples loaded were 
equal to 30μl. Elution speed of 0.14 ml/min; collected fraction volume of 1 ml. 
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Figure 25 shows that cellular PGs in COG7 cells are different than those in E42 cells. This is 
consistent with the radioactive gel images (Figure 13) and chromatographic data (Figure 21). 
It also confirms the fact, that CS PGs constitute a minor fraction of the cellular PGs in 
healthy fibroblasts, where HS is the major part. 
It is clear, that HS is present in COG7 cells, as well as CS is. Moreover, the CS is present on 
heavy and medium mass PGs (peaks at fraction coefficient 0 (heavy) and 0.40 (medium 
weight)). 
3.4 Mass spectrometry 
Mass spectrometry (MS) is a powerful tool used in biochemical and molecular biology 
research in many aspects. The most used quality of MS is the ability to identify peptides, and 
in turn proteins based on their molecular mass (Mw). In this project MS was used to identify 
potential differences between the above two cell types. 
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Table 1. Mass spectrometry analysis results for COG7 and E42 M samples against a human database. Table 
shows only PGs hits. Results arranged by score. M samples of 5.0 ml volumes were dialysed [section 2.9] and 
eluted through ion-exchange column [section 2.10] and collected in elute 1. Elute 1 was analysed via MS. 
It seems that the control fibroblasts possess greater heterogeneity among its secreted PGs. E42 
cells secrete at least nine PGs, compared with only five secreted by COG7 cells. Moreover, 
some PGs secreted by COG7, are not present in E42 M: aggrecan and serglycin. On the other 
hand, there are a number of PGs that are absent in COG7 cells: CD44 antigen, Syndecan-1, 
Neuropilin-1 and glypican. 
MS data was an indicator for further research in order to establish more information about 
nature of PGs present in and secreted from COG7 cells. The differences observed so far are 
interesting. 
There is no MS data concerning CL of COG7 due to technical limitation of obtaining 
sufficient amount of a viable sample. 
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3.5 Western Blotting 
3.5.1 Introduction 
Western blotting is an analytical method that uses antibodies to detect proteins of interest. In 
PG analysis there are many of available antibodies that could be used. 
In theory, Western blotting is based on protein separation in SDS-PAGE gels, based on their 
size and a subsequent transfer to and detection in a membrane.. On that membrane, proteins 
are detected by incubation with antibodies that are specific against the target proteins. 
There are essentially two types of Western blots: semi-dry and wet. The nomenclature of the 
types comes from the protein transfer method that is used in the transfer step. Semi-dry blots 
are used for analysis of membrane and hydrophobic proteins, while wet blots are used for 
more globular proteins.  
In PG Western blot analysis, one can divide the used antibodies into two types: anti-protein 
core and anti-STUB. STUB antibodies bind to epitopes that appear after enzymatic digestion 
of GAG chains. Those antibodies can recognize sulfated sugars that have sulfate substitutes at 
different positions at sugar chain. C6S, C4S are sugars that have sulfate groups at 4
th
 and 6
th
 
carbon in a saccharide, respectively. C0S-STUB defines an epitope without any sulfation. 
Antibody recognition of PG protein cores may sometimes require prior enzymatic removal of 
the GAG chains, while others are claimed to work also in the presence of GAG chains. Some 
antibodies have also been directed towards epitopes residing in GAG chains 
 
 
 
 
 
. 
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3.5.2 Overview; anti-STUB & anti- aggrecan   
 
Figure 26.  Western blot analysis of COG7M and COG7 CL with anti-C4S STUB antibodies. Consecutive wells 
have different sample volumes. Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. 
Membrane exposed for 5 min on CCD camera at luminescence setting; “-“control well.  
This WB shows that there are different PGs present in CL and M fraction of COG7 cells. 
Differential sequence of sample volume was used in order to determine the suitable sample 
size. It is clear that the CL fraction has a lesser amount of PGs, which is shown by weaker 
signals of the bands at COG7 CL 16 μl when compared with COG7 M 16 μl. This difference 
in amount of PGs between CL and M depends on many factors, one of which is the time 
allowed for secretion. Moreover, the high molecular mass PGs are in majority for the secreted 
PGs- this is showed by the strong bands in the upper region of the blot. It is clear that COG 
7CL PGs have C4S STUB epitopes at a Mw of 75 kDa, which is missing for the secreted PGs. 
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There are some similarities between the two fractions. At Mw of 50 kDa both fractions show 
bands, although the band is stronger in M. 
Figure 27. Western blot of COG7 M and CL fraction with an anti-aggrecan antibody. Membrane developed with 
1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD camera at luminescence 
setting; “-“empty well. 
It is clear that the M contains a significant amount of aggrecan. This is in contrast to the CL, 
which possesses significantly less aggrecan. It is clear that secreted aggrecan comes in three 
isoforms. It is a possible explanation for the presence of a ladder with different molecular 
masses. Isoforms 2 and 3 have reduced molecular mass with 246 and 239 kDa respectively; 
isoform 1 is reported as having a canonical “sequence” (Uniprot n.d.). 
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Figure 28. Western blot of COG7 CL with C6S-, C4S- and C0S- anti-STUB antibodies, and anti-aggrecan 
antibodies. Sample size 16 μl/well; Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. 
Membrane exposed for 5 min on CCD camera at luminescence setting; CTR- control 
This blot shows the expression of STUB epitopes in the cellular PGs. It is clear, that the most 
prevalent STUB is C0S, where there is possibly none or little C6S sulfation of the STUB. 
Moreover C4S STUB shows great heterogeneity which is different from what is seen for the 
C0S STUB, which seems to be homogenous. Probably only one PG has this STUB epitope 
and it is most likely aggrecan. The presence of aggrecan is shown in Figure 28  and in Figure 
27, but the prevalence of aggrecan in Figure 27 is low. The reason for this discrepancy could 
be that a strong signal that is coming from the M “consumes” all the substrate and/or all of the 
antibodies and leaves little signal for the CL fraction. In the Figure 28, the anti-aggrecan part 
of the blot was incubated separately and thus the prevalence of anti-aggrecan antibodies and 
the availability of substrate were greatly increased. This, possibly, increased the sensitivity of 
the detection and a low but significant abundance of aggrecan could be detected.  
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Figure 29. Western blot of COG7 M with anti-STUB antibodies and anti-aggrecan antibodies. Membrane 
developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD camera at 
luminescence setting; CTR- control. 
Figure 29 demonstrates the presence of STUB epitopes on the PGs in the M of COG7 cells 
after cABC treatment and the presence of aggrecan in the same fraction. It is clear that 
secreted PGs possess epitopes for all the STUB antibodies tested. This is less certain for the 
cellular PGs, but still possible, but the C6S-STUB epitope gives at best only a very weak 
signal in the CL. However, the internal heterogeneity of C4S-STUB in the M is lower (two 
distinctive bands), when compared to the CL (possibly five bands, Figure 28). 
The weaker signal in the anti-aggrecan COG7 M CTR lane could in fact be due an 
enhancement of the epitope accessibility after enzymatic removal of the GAG chains from the 
aggrecan protein core. 
One can notice that the bands are shown in white against dark background. This deviation 
from standard was caused by corruption of the original file, which rendered it unreadable and 
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therefore a back-up image was used. Nonetheless, the conclusions from both pictures are 
similar. 
3.5.3 Anti-serglycin & Anti-decorin 
Serglycin and decorin are two PGs that were indicated to be present in COG7 cells by mass 
spectrometry. 
 
Figure 30. Western blot of COG7 M and CL with anti-serglycin and anti-decorin. 16 μl of sample /well. 
Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD 
camera at luminescence setting; CTR- control. 
Figure 30 confirms observations by MS with respect to the Ms. However there is more 
information that could be drawn from the above figure: 
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1. Serglycin PG is modified in the COG7 M fraction by a modification other than CS 
chains. I is possible that band at 50 kDa in the anti-serglycin lane for COG7 M is 
either a serglycin bound to other molecule (Malla et al. 2013) or a non-specific band. 
2. This modification is extensive, raising the Mw from 17.5 kDa (protein core) to 
approximately 50 kDa; difference of 32.5 kDa. 
3. Decorin PG is modified with CS chains. This modification contributes approximately 
2 kDa. 
4. There is no serglycin in the CL of COG7 cells. 
5. There are two decorin bands in the CL at 150 kDa and 60 kDa. Such high Mw of 
decorin protein is puzzling and presence of two bands in the cABC lane, compared to 
one of 150 kDa in the control lane indicates that 60 kDa band is modified with CS. 
The 150 kDa band could be an unmodified trimer of decorin, or decorin modified with 
something else than CS. 
 
Figure 31. Western blot of E42 M fraction against anti-C4S-STUB, decorin, serglycin and aggrecan. 16 μl of 
sample/well. Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 
min on CCD camera at luminescence setting; CTR- control. 
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The blot indicates that decorin, serglycin and aggrecan PGs are not present in the M of E42 
cells. Moreover, there is no evidence for C4S-STUB epitopes on the secreted PGs after cABC 
treatment. However, decorin is present in the MS data (Table 1) in the E42 M sample, which 
implies that the procedure could be repeated with more samples.   
 
Figure 32. Western blot of E42 M against anti-C4S-STUB and decorin. 8 μl of sample/well; Membrane stripped 
prior to 1
st
 Ab incubation. Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane 
exposed for 5 min on CCD camera at luminescence setting; CTR- control. 
This blot was carried out to confirm presence of decorin in the E42 M fraction. It is clear that 
decorin is present and that some of its modification is CS. The fully glycosylated form has a 
Mw of approximately 70 kDa and is shown as a smear. However, this indicates that there are 
multiple different variants which follow the current literature (3 possible N-glycosylation 
sites; 1 possible O-glycosylation site)(Uniprot n.d.). However, the presence of the C4S-STUB 
epitope on this blot is contradictory to previous observations. This is the only time, where 
C4S-STUB epitope was visualized on E42 M fraction. It could be that since the membrane 
was stripped before re-probing that there is a residual signal from a previous blotting 
procedure or there is in fact C4S-STUB epitope which was only visualized on this membrane. 
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This issue needs to be resolved in the future. However, looking at this blot alone, the 
alignment of the band at 49 kDa between E42 M C4S-STUB and anti-decorin (cABC) suggest 
that decorin has C4S-STUB epitope in E42 M. 
 
Figure 33. Western blot of COG7 M and CL with anti-serglycin and anti-decorin antibodies. 16 μl of 
sample/well. Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 
min on CCD camera at luminescence setting; CTR- control 
This Western blot shows that decorin is not only present in M, but also in the CL of COG7 
cells. However, the nature of decorin present in the CL is somewhat different from the 
secreted variant. It is clear that decorin from CL is not modified by CS and that it forms some 
kind of complexes (or oligomers) of high molecular mass (approx. 250 kDa). This possible 
multimerization is also seen in the M, but to a lesser extent (shown by the band at 250 kDa). 
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Figure 34. Western blot of E42 M against anti-C6S-, C0S-STUB, biglycan and aggrecan; 8 μl of sample/well. 
Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD 
camera at luminescence setting; CTR- control 
This Western blot shows that there is no detectable C0S-STUB epitope in E42 M fraction. 
Moreover, it shows that there is also no detectable aggrecan in E42 M, which supports the 
previous findings: MS data (Table 1, Figure 31). The novel information coming from this 
experiment is the presence of biglycan (weak band at 100 kDa), even though it was shown in 
MS data (Table 1), this gives more evidence to its presence. The most prominent mark on this 
blot is the strong signal originating from anti-C6S-STUB antibody. Lack of signals from other 
STUBs (C40S- no signal (Figure 31) and C4S-only one membrane (Figure 32)), proves that 
one of the STUBs epitopes present in secreted glycans from E42 is C6S, whereas C0S is 
absent and C4S is doubtful. 
 RESULTS 
 
60 
 
 
 
Figure 36. Western blot of CL from COG7 and E42; 8 μl of sample/well. Membrane developed with 1.0 ml of 
ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD camera at luminescence setting; CTR- 
control 
Figure 35. Western blot of E42 M against anti-biglycan; 8 μl of sample 
per well. Membrane developed with 1.0 ml of ECL Detection Reagent for 
5 min. Membrane exposed for 1 minute on CCD camera at luminescence 
setting; CTR- control. 
This blot is another experiment that supports the MS data. 
There is biglycan present in E42 M with CS modification. 
There are no known biglycan isoforms (Uniprot n.d.). This 
possesses the question about the 30 kDa band and its nature. 
Possibly this band is a result of an unspecific binding of the 
anti-biglycan antibodies.  
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There is an indication of the presence of decorin in CLs of COG7 cells, but no signal from 
E42 CLs. However, the Mw of decorin indicated on the gel does not correspond to the 
theoretical value (39 kDa). It is possible that decorin in COG7 CL is modified with something 
else than CS. 
The presence of four, distinctive bands shows that decorin can form oligomers. The “heavy” 
bands (top of the gel, approximately 250 kDa) could be such oligomers. Similar band patterns 
could be observed in Figure 33. 
 
Figure 37. Western blot of COG7 &E42 M samples against decorin and aggrecan; 8 μl of sample/well. 
Membrane developed with 1.0 ml of ECL Detection Reagent for 5 min. Membrane exposed for 5 min on CCD 
camera at luminescence setting; CTR- control. 
This blot clearly shows the potential abundance difference in decorin levels in between COG7 
M and E42 M, which is supported by the MS data (Table 1). It also shows that there is no 
 RESULTS 
 
62 
 
aggrecan present in the CL of E42, in contrast to COG7, where aggrecan is abundant. There is 
small difference upon cABC digestion in the cellular aggrecan (reduction of peak intensity at 
250 kDa), but no shift in molecular mass- which corresponds to fact that aggrecan protein 
core is 250 kDa itself. However the mass change of aggrecan is difficult to observe at the 
upper region due to the fact that neither aggrecan with CS nor without CS could have entered 
the SDS-PAGE gel properly. Perhaps the binding of anti-aggrecan antibodies is dependent on 
CS level and the amount of GAGs attached to the core. The increased signal level of the upper 
band area (>150 kDa) in cABC treated decorin could indicate that the presence or absence of 
CS is influential on the formation of heavy weight aggregates. 
3.6 Protein biochemical analysis 
3.6.1 Protein synthesis level- BCA™ Protein Assay 
From the Western blot analysis, it was clear that COG7 and E42 possess different 
characteristics with respect to protein core synthesis. In order to establish whether the COG7 
cells secrete or produce different amounts of proteins when compared to control fibroblasts, a 
protein quantification experiment was carried out using BCA™ Protein Assay. 
 
Figure 38. BSA standard curve with the lysis buffer used as a solvent. Absorbance values taken at 562 nm 
wavelength. 
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Figure 39. BSA standard curve. DMEM without bovine serum used as a solvent. Absorbance values taken at 562 
nm wavelength. 
Standard curves created for known concentration of bovine serum albumin (BSA) were used 
to establish the unknown concentrations in the samples. Figure 38 was used when analysing 
the CLs samples, whereas Figure 39 was used for analysis of M samples. 
 
Figure 40. Protein measurement using BCA™ Protein Assay in COG7 and E42 samples from M and CL. Values 
given in μg/ml of analyte. 
The COG7 samples contained much more protein than the E42 samples, both for the media 
and cell fractions.  
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This significant difference, especially in M sample, has given some experimental challenges 
when it comes to loading gels with equal amounts of proteins and during detection of high-
levels signals in Western blots.  
3.6.2 The protein patterns of Ms and CLs- silver staining 
Silver staining was performed in order to further characterize the proteins present in the 
COG7 M & CL. 
 
Figure 41. Silver staining of COG7 CL & M, E42 CL & M and COG8 M. Sample size of 8 μl/well. M and CL 
samples were loaded directly onto the gel from harvested Ms, without any dilution or prior ion-exchange step. 
The silver stain was developed as per section 2.13 with development time of 4.5 min. 
Silver staining has shown clearly that there is a large difference in the protein concentration 
between COG7 and E42 cell types in both CL and the Ms. There is a very strong band at 60 
kDa in COG7 M which corresponds to serum albumin (unpublished data, personal 
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correspondence with Anders Moen). Presence of significant amounts of bovine serum 
proteins was confirmed by MS for the COG7 samples, but not for the E42 M samples. The 
source of bovine albumin was traced to serum additive from complete medium. The 
difference between the two cell lines in this respect, that both were subjected to a procedure 
that is designed to remove serum proteins before collection of secreted macromolecules in 
serum-free medium, indicates a prolonged residence time of endocytosed serum proteins in 
COG7 cells. This could be a result of a delayed recycling of endocytosed material, which 
occurs efficiently within 15 min in normal mammalian cells. This finding is interesting and 
requires further investigation. 
3.7 Ion-exchange chromatography 
3.7.1 Introduction 
Ion-exchange chromatography allows for separation of molecules based on their affinity to 
the ion moiety on the column. It is a method used for separation of different molecules, 
including proteins and PGs. 
In analysing PGs, ion-exchange is used to separate these highly negatively charged molecules 
from other proteins. Glycans (PGs also) carry negatively charged groups (sialic acid for 
glycans, and sulfate modifications and glucuronic acid for PGs). PGs, however, are the most 
negatively charged macromolecules, which allows for separation of most PGs from other 
proteins. PGs bind strongly to positively charged DEAE columns and are retained until the 
salt gradient reaches a concentration allowing for displacement of PGs from the column. In 
this experiment, where stepwise elution was performed, most PGs should elute in elute 2. 
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3.7.2 COG7 M ion-exchange profile on Silver stained gel 
 
Figure 42. Silver stained gel after ion-exchange chromatography of COG7 M fraction. “1:9 D” represents 1 in 9 
dilution of the sample in water. Elute 1- proteins eluted in low salt buffer (0.1 M NaCl). Elute 2- protein eluted 
in high salt buffer (1.0 M NaCl). Elute 3 – proteins eluted at high salt buffet (1.0 M NaCl) immediately after 
elute 2. 
It is clear that some PGs from the M fraction have been retained on the column and were 
eluted in the elute 2. Most of the PGs have high Mw (>100 kDa), although there is one strong 
band at approximately 60 kDa. Unusually, this band is persistent in elute 1 as well and it 
shows as very strong peak in Figure 41 (COG7 M lane). This could be due to high levels of 
this protein, that it shows in elute 2. It is simply retained in column due to high abundance or 
it could be simply different PG or a protein. 
1:9 dilutions were performed in order to achieve better band separation and, therefore, 
identification. 
Top bands (>150 kDa) and  the strong bands at approx. 60 kDa from Elute 2 were cut out 
from the gel and analysed by MS in order to detect possible PGs, but no new candidates were 
found. However, strong presence of bovine serum albumin was confirmed. 
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4 Discussion 
The aim of this project was to investigate PG synthesis and modification in COG7 cells. PG 
synthesis in COG8 deficient cells were at the same time investigated by another student. 
Since it is established that cells with dysfunctional COG-complex have distorted N-
glycosylation and O-glycosylation (Freeze & Aebi 2005; Ng et al. 2007), it is logical to 
assume that PGs could be affected as well. Mutations in COG complex were discovered in the 
six of its eight sub-units :COG1,COG2, COG4, COG5, COG6 , COG7 and COG8 (Foulquier 
et al. 2006; Reynders et al. 2009; Paesold-Burda et al. 2009; Lübbehusen et al. 2010; Wu et 
al. 2004; Foulquier et al. 2007; Zeevaert et al. 2008), with COG2 mutation being the most 
recent discovery (Kodera et al. 2014). 
COG1, COG4, COG7 and COG8 showed lack or decrease in sialyation on the N-glycans with 
COG1 having least amount of sialyation and COG4 showing the highest amount of sialyation. 
11% of N-glycans in COG1 have agalactosylated N-glycan structures(Reynders et al. 2009). 
In COG7 cells the level ST-antigen was reduced but T-antigen O-glycan remained 
unchanged. The ratio between T and ST antigens was higher (0.11) than control (0-0.056) 
(Xia et al. 2013).  
N-glycosylation and O-glycosylation defects in COG7 patients are described in details. The 
prevailing defects in N-glycosylation are decrease in sialyation and the high (40%) percentage 
of agalactosylated glycan structures. Membrane bound surface O-glycans have reduced level 
of sialyation and reduction of activity of CMP-sialic acid and UDP-galactose transporters as 
well as reduction in activity of several galactosyltransferases have been reported. (Reynders et 
al. 2009; Ng et al. 2007; Shestakova et al. 2006; Zeevaert et al. 2008). However, as of May 
2014 there is no literature regarding COG7 deficiency and PG synthesis. Judging by the 
presence of N- and O-glycosylation defects in COG7 patients, it is safe to assume that PG 
synthesis would be affected too. To investigate PG synthesis in COG7 cells, radioactive 
metabolic labelling followed by size-exclusion gel chromatography, Western blotting, and 
mass spectrometry techniques were applied. Regretfully, COG7 cells begun to demise in 
viability sometime after procurement and during the remaining course of the project no more 
new samples were available to perform more experiments. 
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It is clear that the PGs synthesized in COG7 cells differ drastically from healthy cells (E42). 
The evidence for that comes from metabolic labelling experiments and analysis of both CLs 
and molecules secreted to the M and their visualization on SDS-PAGE gel. The PGs 
synthesized by COG7 cells show a higher molecular mass than the corresponding for control 
cells (Figure 10, Figure 11) These differences in molecular mass might be a result of extended  
GAG chain length and/or differences in the sulfation level, but could also be a result of 
differences of protein core masses or complex formation of modified protein cores (however, 
secreted decorin by E42 and COG7 cells has similar mass, that follows the predicted value 
(Figure 30, Figure 32) of decorin). The molecular mass of the modified PGs in COG7 cells 
differs also from those produced by COG8 and COG4 mutants, which suggests that COG 
mutations have sub-unit specific consequences in PG biosynthesis (Figure 10, Figure 11).The 
striking is also the difference in expression diversity between healthy cells and COG7 cells. 
COG7 cells display only two bands of PGs in the secreted fraction (M) whereas E42 show a 
greater heterogeneity (Figure 10, Figure 11).  
One of the possible reasons for reduced diversity in the secreted PGs in COG7 cells could be 
unavailability of substrates or enzymes needed for proper modification. This hypothesis 
would fall into the idea of the COG complex functioning as a retrograde transport facilitator 
(Shestakova et al. 2006; Bruinsma et al. 2004; Ungar et al. 2006) in both the vesicular and 
maturation protein transport model of  the Golgi apparatus. Simply COG is unable to take part 
in the retrograde transport of the Golgi resident enzymes that are inevitably moved from cis to 
medial to trans -cisternae along with cargo molecules while the cisternae progress (mature) 
through the Golgi. In the vesicular transport model only some resident Golgi enzymes are 
transported along with cargo molecules, thus a little retrieval is needed for the lost enzymes. 
The resident Golgi enzymes cannot follow the default return route to newly formed cisternae 
at cis site. 
While HSPG synthesis is reported to take place in the medial Golgi region, CSPG synthesis 
has been shown to occur very late in the Golgi apparatus in most cell lines studied. There are 
several examples that enzymes involved in HSPG synthesis return to the ER upon Brefeldin A 
treatment, while enzymes involved in CSPG synthesis do not, indicating a localization in the 
trans Golgi network (reviewed in Prydz & Dalen 2000).  Thus, if HSPG synthesis fails early 
in the medial Golgi region, more sites could become available for CS GAG polymerization. 
This might not, however, explain a 4-fold increase in the secretion of CSPGs. This increase 
 DISCUSSION 
 
69 
 
could also be related to the cellular homeostasis of CSPGs, where under normal 
circumstances, a significant fraction of the CSPGs synthesized are routed towards degradation 
in a microtubule-dependent manner (Fagereng et al. unpublished observation). While the 
existence of GAGosomes, an assembly of enzymes involved in GAG synthesis, has been 
proposed for both HS and CS synthesis, the organization and turnover of the enzymes 
involved is not fully known. Thus, why CSPG synthesis is not inhibited, while HSPG 
synthesis is, requires more experiments to find out. 
Secondly the reason for reduced diversity in secreted PG in COG7 cells could be induced by 
an impaired signalling pathway. PGs are involved in cell signalling (Bartus et al. 2012; 
Schaefer & Schaefer 2010; Hildebrand et al. 1994) and therefore altered PG secretion will in 
turn affect PG expression in a type of negative feedback loop. This might be the case in 
COG7 cells where due to improper glycosylation of PGs, those molecules cannot function 
properly and thus would affect signalling (Büttner et al. 2013). 
The striking characteristics of secreted COG7 PGs are that these are almost exclusively 
modified by CS (Figure 12, Figure 17 ). One could understand this modification as over-
polymerization with CS, but it also could be viewed as under-polymerization of HS.  The 
current understanding of HS PGs (HSPG) is that they are involved in modulation of signalling 
(Hufnagel et al. 2006) and mediation of the formation of efficient ligand-receptor complexes 
(Eswarakumar et al. 2005). HSPGs are needed for binding of fibroblast growth factors (FGFs) 
to their cell surface receptors (Yayon et al. 1991; Eswarakumar et al. 2005). The HSPGs do 
not transmit the signal, but act as accessory molecules that potentiate the signal. Thus, under-
HS modification on a PG could lead to reduced FGF binding effectiveness on the COG7 cell 
surface. Even though it is not clear whether the PGs in the M only are secreted molecules, 
PGs that eventually are shedded from the cell membrane would also be present in the M. The 
most frequently shed PGs are members of the syndecan PG family, mostly carrying HS 
chains. The shedding has been reported to be influenced by the extent of GAG modification. 
Compiling the fact that the amount of HS in COG7 CLs is lower than in E42 CLs (Figure 14) 
and that HS modification relatively speaking is marginal on PGs found in the M of COG7 
cells (Figure 15), it is possible to suggest that COG7 cells would have a distorted FGF 
signalling.   
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Since the sulfate incorporation, as a single analysis, is only semi-quantitative, it is difficult to 
draw conclusions regarding the number of GAG chains and the level of sulfation of individual 
chains. 
While considering HS modification, it is clear that PGs synthesized in COG7 cells are less 
modified with HS. This is observed bot for cellular PGs (CL fraction) and in the M (Figure 
14, Figure 15). Control fibroblasts extensively modify secreted PGs with HS, while COG7 
cells do this to a much lesser extent. It is clear that secreted PGs from E42 have substantial 
HS modification (40 % HS). When compared this value to that for PGs secreted from COG7 
cells (5 % HS), it is clear that reduction is significant. 
Shestakova et al in 2006 showed that in COG7 knock-down (KD) cells, GlcNAc T1 enzyme 
is severely mislocalized from evenly distributed across the Golgi stacks (Röttger et al. 1998)to 
dispersed vesicles throughout cytoplasm with glycosylation defects occurring earlier in the 
glycosylation pathway (Shestakova et al. 2006). Even though GlcNAcT1 is not directly 
involved in HS polymerization, it is clear that mislocalization of Golgi resident enzymes in 
COG7 cells could occur. EXT1 and EXT2 were shown to localize in the cis-Golgi in  
(Multhaupt & Couchman 2012) and  EXT1 and EXT 2 are enzymes involved in 
polymerization of HS chains (Kreuger & Kjellén 2012b). Moreover, knock down studies of 
EXT1 showed that EXT1-deficient embryonic bodies showed increased biosynthesis of CS 
(doubled production), while HS synthesis was absent (Le Jan et al. 2012). In theory, 
hypothesized by Kreuger & Kjellén, reduced synthesis of HS leaves “open” linkage regions 
for CS synthesis that otherwise would be occupied by HS. Moreover, lack of HS biosynthesis 
would increase the amount of PAPS and UDP-sugars available for CS synthesis (Kreuger & 
Kjellén 2012b). However, the radioactive sulfate incorporation in the fraction of 
macromolecules secreted from COG7 cells was several times higher than for control 
fibroblasts (Fig 1). This indicates increased CS synthesis, since this sulfate was mostly 
removed by chondroitinase treatment. The possible contribution of an increase in PG protein 
core synthesis or increased GAG chain lengths was not addressed. Regrettably, 
3
H-
glucosamine  and 
35
S Met labelling was not performed in this thesis, so the contributions from 
changes in GAG chains and PG core protein synthesis was not addressed by metabolic 
labelling. 
Non-radioactive M and CL samples were prepared for mass spectrometry. In an ion-exchange 
chromatography step, the PGs were isolated from the bulk of proteins in the samples. From 
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the metabolic labelling studies, secreted PGs showed greater heterogeneity in E42 control 
fibroblasts, than in COG7 cells. In fact, COG7 secreted PGs show only two fractions of 
sulfated PGs and those are of high Mw (Figure 12, Figure 20). The MS data provided insight 
into the M composition and it supports the compositional diversity. In COG7 M the most 
abundant PG was biglycan followed by lumican whereas in E42 M the most abundant PG was 
chondroitin sulfate proteoglycan 4 followed by decorin, although decorin and lumican 
abundance in E42 M was nearly equal The reason for this expressional diversity is not clear. 
It is possible that MS intrinsic limitation lead to skewed results for the analysis of M samples 
from COG7 cells. COG7 M samples showed a high protein concentration. This could 
correspond to a general increase in protein secretion, as observed for PGs, but the samples 
had especially high levels of serum bovine albumin also when compared to control cells. This 
high level of protein could reduce the sensitivity of mass spectrometry where in M samples 
from control cells, the protein level was at an appropriate level for MS analysis (Anders 
Moen, personal correspondence). On the other hand, after ion-exchange chromatography 
followed by silver staining, MS analysed samples from elute 2 did not show any previously 
undetected PGs.  
PGs may also be analysed by Western blotting when the appropriate antibodies are available. 
In many cases, removal of the GAG chains is required for the antibody to recognise the 
protein core in question. The PG decorin was present in M from both control fibroblasts and 
COG deficient cells (i.e. COG7 M and E42 M). The secreted variant does not differ 
extensively between the normal and COG7 cells. The only significant difference is the level 
of CS modification. COG7 M expresses decorin that is modified not only with CS, but does 
also possess another type of modification. This is in contrast to E42 M, where the fraction of 
secreted decorin is fully glycosylated with only chondroitin (showed in Figure 32, where the 
39 kDa band is present). It is possible that the differently glycosylated decorin is needed for 
proper tissue functionality. It is possible that GAG synthesized on COG7 decorin is a hybrid 
chain or that there are more than one chain, but the latter option is less likely since there is 
only one known O-glycosylation site on decorin protein core (Uniprot.).However, there are 3 
N-glycosylation sites present on decorin. It is possible that there is altered use of those sites 
due to mislocalized transferases. 
The CL of COG7 cells showed unusual results with the anti-decorin antibody (Figure 33). 
Where there is, possibly, no decorin present in E42 CL, the COG7 CL demonstrated a ladder-
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like pattern. It seems that the decorin remaining in the CL of COG7 cells is not modified by 
CS. It is possible that decorin, in the cell fraction, has not yet reached the chondroitin 
polymerization enzymes, which are located at the trans-side of the Golgi apparatus. This 
would imply rapid cellular release upon CS modification. Secondly, if we assume that decorin 
is modified with a hybrid chain, it is possible that elongation of the chondroitin chain cannot 
proceed without initial polymerization of HS on the same protein. However, there is no 
evidence indicating a presence of a hybrid HS/CS chain(s) on COG7 CL decorin. It is much 
more probable that N- and O-glycosylation sites are occupied by keratan sulfate since keratan 
sulfate can originate from both N- and O-glycan sites. Yet, there is secretion of CS –modified 
decorin in the COG7 cells (Figure 30). It is entirely possible that there is some HS 
polymerization activity, but its rate of polymerization does not connect with the ongoing 
protein synthesis. This reduction in polymerization of heparan could be due to a slow rate of 
retrograde transport of heparan polymerizing enzymes from trans- and medial- to cis- 
cisternae in the Golgi apparatus. Therefore, since only 20 % of the nominal COG complex 
level is present in the COG7 patient (Wu et al. 2004), this overall retrograde transport rate 
could be significantly slower This transport retardation could, in turn, influence the overall 
polymerization rate of HS. 
The presence of the “decorin ladder” in COG7 CL could be explained twofold. Firstly, the 
small differences in molecular mass between bands (approximately 2-4 kDa) are, most 
probable, due to the number of N-glycosylations. Decorin has three potential N-glycosylation 
sites and using combinations of all three sites or none can lead to significant variation in mass 
(Uniprot). Secondly, the presence of heavy bands at 150 kDa could be explained by either the 
presence of decorin clusters (multiple decorin molecules aggregating together) or that decorin 
is coupled to some other protein complex. It is most probable that band showed at high 
molecular level is decorin bound to collagen type I or type II (Uniprot). Collagen is the 
prevailing protein in the fibroblasts and its binding to decorin is well known. The heavy Mw 
decorin is present as a secreted variant in E42 M (Figure 37) and to some extent in COG7 M. 
It is unclear what characteristics this variant shows, but it is clear that it is CS modified to 
some degree. This modification could influence its aggregation properties.  
When analysing the protein content and composition of media and cell fractions from control 
fibroblasts and COG7 cells, these were first washed and incubated in serum-free M, following 
a procedure designed to avoid such external proteins in the samples. The initial image after 
 DISCUSSION 
 
73 
 
silver staining indicated dramatic increase in the protein levels for the samples from the 
COG7 cells, but MS revealed that there was a dramatically higher content of bovine serum 
proteins in these samples, when compared to the control samples. This is most easily 
explained by a prolonged retention of serum proteins in the COG7 cells. The same 
phenomenon was observed also for COG8 cells (Anders Moen, personal communication), 
Since the washing procedure designed to remove serum proteins includes a 30 min incubation 
where internalized proteins would normally be released by recycling, does the fact that these 
proteins appear in the M in a subsequent incubation period for cells deficient in COG7 and 
COG8 indicate that recycling to the cell surface is delayed in these cells. However, further 
experiments are required to establish this possibility. 
4.1 Future studies 
The duration of master studies program is limited. Therefore some of the analysis shows 
incomplete or conflicting data. Thus, with no doubt, there is a strong need for repeat of 
experiments to validate the results obtained. 
Due to failure to thrive of COG7 cells during a period of time, it would be beneficial to 
establish a system that would provide a researcher with new samples swiftly. A knock-down 
protocol could be used. 
It is of paramount importance to carry out 
3
H-glucosamine and 
35
S-Met labelling on COG7 
cells to establish the exact characteristics of the GAGs on the PGs and address the issue of 
increased sulfate labelling. 
35
S-SO4
2-
 labelling is powerful method, but to establish a full 
experimental picture, 
3
H-glucosamine and 
35
S-Met labelling is also needed. More work 
should be carried out in CL fraction studies with respect to MS and Western blotting. 
Regretfully, E42 CL fractions did not produce sufficient amounts of protein, thus a 
functioning protocol should be established in order to achieve the desired protein 
concentration both for the CL and the M. 
Fluorescent labelling and confocal visualization of the Golgi resident enzymes should be 
performed. It would be interesting to carry out localization studies on two HS polymerizing 
enzymes: EXT1 and EXT2 in COG7 cells. It is possible that EXT1 and EXT2 co-localize 
with CS polymerizing enzymes in the trans-Golgi region. Such localization would explain the 
reduced levels of HSPGs produced in COG7 cells. 
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Recycling studies should be carried out on COG7 cells to investigate the recycling 
phenomenon indicated in this thesis. Following the idea that the COG complex is involved in 
intra-Golgi retrograde recycling of protein, it could also be involved in a number of other 
retrograde transport processes. It would be interesting to assess how COG7 cells recycle 
proteins endocytosed from the extracellular environment.  
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6 Appendices 
6.1 G-50 Fine columns creation 
The columns used in metabolic labelling were created in-house, following the procedure: 
1. Old 10 ml plastic pipettes were cut at the 7 ml volume level mark. Bottom part  that 
contained nozzle was kept and rest of the pipette was discarded 
2. Small portion of glass wool was placed and compacted at the inside part of the nozzle. 
The amount of glass wool used should be enough to keep gel material from leaking 
through nozzle 
3. 4.0 ml of G-50 fine gel material was placed. G-50 fine was pre-soaked in dH2O 
following the manufacturers manual 
4. Column  then was let to stand in order to settle the gel material 
 
6.2 List of used equipment throughout the 
project 
 
Name Model Manufacturer 
Air incubator DH Autoflow NuAire 
Balance BP2215 Satorius 
Balance 1212MSCS Precis 
Rubber Policeman Cell lifter 3008 Costar 
Cell culture flasks 75 cm2
 
 Nunc 
Centrifuge GS-15 R Beckman 
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Centrifuge Allegra X-22 Beckman-Coulter 
Dialysis Cassette Slide-A-lyser Pierce 
Eppendorf Centrifuge Mini-spin Eppendorf 
Exposure Cassette Storage phosphor 
cassette 
GE Healthcare 
Freeze-dryer Maxi dry lyo FD1.0 
Gel cell XCell sure lock Novex 
Gel cell Criterion Cell BioRad 
Heating block DRI-Block DB20 Techne 
Hotplate magnetic stirrer 345PR Snijders 
Image Eraser Image Eraser #810-
UMW 
Amersham Biosciences 
Light Microscope DMIL Leica 
Light Microscope Lens 10/0.25 Leitz-Weltzar 
Orbital Shaker Gerhardt Abshake 
pH meter 420A+ Thermo Orion 
Power supply Bromma 2301 LKB 
Scintillation counter 1900TR Packard 
Scintillation vials Mini-vial 6 ml Sarstedt 
Slab gel dryer SGD4050 Savant 
PhosphoImager Typhoon 9400 Amersham Biosciences 
Ultra-deep freezer (-80°C) MDF Panasonic 
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Vertical shaker USR-50 Pro Labplus 
Vortex mixer Whirlimixer Fisons 
Water bath Tempette Junior TE-8J Techne 
 
6.3 List of chemicals and expendables  
Name Catalogue # / Lot/ Name Producer 
20 x  WB Transfer buffer NP0006-1 Novex 
20 x MOPS-SDS Running 
buffer (BioRad) 
XT-MOPS #161-0788 BioRad 
20 x MOPS-SDS Running 
buffer (Novex) 
NP0001 Novex 
20 x Reducing Agent XT Reducing agent 20 x #161-0792 BioRad 
35
S-SO4
2- 
Sulfate Lot# 177911 Perkin-Elmer 
4x Sample buffer XT Sample Buffer #161-0791 BioRad 
6 well plate 6 well culture cluster, # 3516 Costar 
Acetic Acid Lot# 33209 Sigma 
Amplify Solution NAMP100V 
Amersham 
Biosciences 
Anti –Mouse IgG Antibody 
conjugated with horseradish 
peroxidase 
NXA93-1ML1, lot # 9489919 GE Healthcare 
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Anti –Rabbit IgG Antibody 
conjugated with horseradish 
peroxidase 
NA934, lot # 9499122 GE Healthcare 
Blocking Agent ECL Advanced Blocking Agent GE Healthcare 
Blue dextran Lot# 283873 
Amersham 
Biosciences 
Bovine Serum Albumin Lot#038K0704 Sigma Aldrich 
Calcium Chloride (CaCl2) Lot# 100K0216 Sigma Aldrich 
CL-6B Gel material Sepharose CL-6B # 17-0160-01 GE Healthcare 
DEAE gel material DEAE Sephacel™ # 17-0500-01 GE Healthcare 
DMEM Lot# 3MB049 Lonza 
DMSO-Dimethylsulfoxide Lot#007165.02 
Duchefa 
Biochemicals 
EDTA Lot#7640065 Sigma Aldrich 
Ethanol - Arcus 
Foetal Bovine Serum (FBS) Lot#A64304-0133 PAA 
G-50 Fine gel material Sephadex G-50 Fine # 17-0042-02 GE Healthcare 
HEPES CAS# 7365-45-9 Sigma Aldrich 
Hydrochloric Acid 20.252.290 VVR 
L-Glutamine Lot#0MB122 Lonza 
Methanol 3221BN-2.5L Sigma Aldrich 
Molecular Marker Magic Marker ™ # LC5602/23 Novex 
Molecular Marker 
Precision Plus Protein™ Unstained 
Standard #161-0363 
BioRad 
Molecular Marker 
Precision Plus Dual Colour Standards 
# 161-0374 
BioRad 
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Molecular Marker 
Protein Molecular Weight Markers 
[methyl-
14
C] methylated 
#NEC811001UC, lot # 1638419 
Perkin Elmer 
Penicillin /Streptomycin (P/S) Lot#0MB129 Lonza 
pH buffers , 4.01, 7.01 , 10.01 #910110 Thermo Orion 
Proteo Silver Plus™ Lot# 080M6259 Sigma Aldrich 
PVDF membrane LC2005 Novex 
RPMI 1640 Medium Lot# 90988M Lonza 
Scintillation Count Liquid Ultima Gold XR Perkin Elmer 
SDS-PAGE Gel 
Criterion XT 4-12 % Bis-Tris #345-
0123 
BioRad 
SDS-PAGE Gel 
NuPAGE 4-12 % Bis-Tris 
#NP0322BOX 
Novex 
Sodium Acetate Lot # 93170 Riedel-deHaen 
Sodium Chloride Lot # K36719833 BDH 
Sodium deoxycholate Lot#61H0536 Sigma Aldrich 
Sodium hydroxide 1040517 SDS 
Sodium Phosphate (dibasic) Lot# 120K0126 Sigma Aldrich 
Sodium Phosphate (monobasic) Lot# 20K0227 Sigma Aldrich 
TRIS 33621.26 VVR 
Triton X-100 789704 
Boerhinger 
Manheim 
Tween 20 - Sigma Aldrich 
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Ultra-centrifuge device, 10 k UFC901024 Amicon 
WB detection reagent 
Amersham™ ECL Select™ WB 
detection reagent # RPM 2235 
GE Healthcare 
6.4 List of buffers and solutions 
 
Name  Composition 
1 x TTBS (Tris-Tween 
buffer saline) 
20 mM Tris, 137 mM NaCl, 0.1 % Tween 20, Adjust to pH of 
7.6 with HCl 
1 x WB Transfer buffer 50 ml 20x WB transfer buffer, 100 ml Methanol, 850 ml dH2O 
10 x PBS, pH 6.8 
18mM Sodium phosphate (monobasic), 84mM Sodium 
phosphate (dibasic), 150 mM NaCl. 1 x PBS (diluted with 
dH2O) would give pH of 7.4. 
2% ECL Advanced 
Blocking Solution 
2 % of  ECL Advanced Blocking agent in 1 x TTBS 
35
S-SO4
2-
Medium 
RPMI 1640 Medium (without sulfate), 1% P/S, 1 % L-
Glutamine, 0.2 mCi/ml of 
35
S-SO4
2- 
sulfate 
Anti aggrecan antibody 
1:2000 dilution 
2.5 μl of Anti aggrecan antibody in 5 ml of 2% ECL Advanced 
blocking solution 
Anti biglycan antibody 
1:2000 dilution 
2.5 μl of Anti biglycan antibody in 5 ml of 2% ECL Advanced 
blocking solution 
Anti C0S-STUB antibody 
1:2000 dilution 
2.5 μl of Anti C0S-STUB antibody in 5 ml of 2% ECL 
Advanced blocking solution 
Anti C4S-STUB antibody 
1:2000 dilution 
2.5 μl of Anti C4S-STUB antibody in 5 ml of 2% ECL 
Advanced blocking solution 
Anti C6S-STUB antibody 
1:2000 dilution 
2.5 μl of Anti C6S-STUB antibody in 5 ml of 2% ECL 
Advanced blocking solution 
Anti decorin antibody 
1:2000 dilution 
2.5 μl of Anti decorin antibody in 5 ml of 2% ECL Advanced 
blocking solution 
Anti serglycin antibody 
1:2000 dilution 
2.5 μl of Anti serglycin antibody in 5 ml of 2% ECL Advanced 
blocking solution 
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Blue dextran/ potassium 
dichromate mix 
3 mg/ml Blue dextran, 2 mg/ml potassium dichromate 
Buffer A (ion exchange) 
0.1 M NaCl, 20 mM Sodium Phosphate (monobasic /dibasic), 
Adjust pH to 6.8 with changing  sodium phosphate monobasic 
to dibasic ratio in solution  
Buffer B (ion exchange) 
1.0 M NaCl, 20 mM Sodium Phosphate (monobasic/dibasic), 
Adjust pH to 6.8 with changing  sodium phosphate monobasic 
to dibasic ratio in solution 
cABC buffer (10x) 
0.05 M Sodium Acetate, 0.05 M Tris, 0.1 % BSA Adjust pH to 
8.0 with HCl. 
CL-6B Size exclusion 
chromatography running 
buffer 
0.15 M NaCl, 0.05 M Tris, 0.2& Triton X-100 
Incomplete medium 500 ml of DMEM, 1%P/S 
Complete Medium 500 ml of DMEM, 10% FBS, 1% P/S, 1 % L-Glutamine 
Fix solution for SDS-PAGE 
and Silver staining 
5:1:4 solution of: Ethanol, Acetic acid and dH2O 
Freezing solution DMEM, 10 % FBS, 1 % P/S, 1 % L-Glutamine, 10% DMSO 
Hep buffer (10x) 
0.05 M HEPES, 0.5 M NaCl, 10mM Calcium Chloride, 0.1 % 
BSA, Adjust pH to 7.0 with HCl 
Lysing buffer 
50 mM Tris-HCl, 150 mM NaCl, 0.05% Triton X-100, 1 mM 
EDTA, 0.05 % Sodium Deoxcholate, Adjust to 7.4 pH with 
HCl 
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6.5 List of primary antibodies 
Epitope Ig Type Lot# Manufacturer 
Aggrecan Rabbit 2000382 Millipore 
C6S-STUB Mouse IgM A80120 Seikagaku 
C4S-STUB Mouse IgG1 2062302 Millipore 
C0S-STUB Mouse IgG A70120 Seikagaku 
Decorin Mouse IgG1 ECI0212111 R&D Systems 
Biglycan Mouse IgG1 WLL02 R&D Systems 
Serglycin Rabbit - Obtained from Achilleas D. Theocharis 
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6.6 Protein Standards 
 
Magic Mark™ XP Western Protein Standard 
 
Precision Plus Protein™ Dual Colour 
Standard 
 
 
 
 
 
 
Precision Plus Protein™ Unstained Standard 
